<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diltiazem: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diltiazem: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Diltiazem: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12384" href="/d/html/12384.html" rel="external">see "Diltiazem: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13233" href="/d/html/13233.html" rel="external">see "Diltiazem: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F160657"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cardizem;</li>
<li>Cardizem CD;</li>
<li>Cardizem LA;</li>
<li>Cartia XT;</li>
<li>Dilt-XR;</li>
<li>Matzim LA;</li>
<li>Taztia XT;</li>
<li>Tiadylt ER;</li>
<li>Tiazac</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866605"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AA-Diltiaz;</li>
<li>ACT Diltiazem CD;</li>
<li>ACT Diltiazem T;</li>
<li>APO-Diltiaz CD;</li>
<li>Cardizem CD [DSC];</li>
<li>Diltiazem CD;</li>
<li>DilTIAZem T;</li>
<li>Diltiazem TZ [DSC];</li>
<li>Diltiazem-CD [DSC];</li>
<li>JAMP Diltiazem T;</li>
<li>JAMP-dilTIAZem CD;</li>
<li>MAR-Diltiazem CD;</li>
<li>MAR-Diltiazem T;</li>
<li>Pharma-Diltiaz;</li>
<li>PMS-Diltiazem CD [DSC];</li>
<li>SANDOZ Diltiazem CD [DSC];</li>
<li>SANDOZ Diltiazem T [DSC];</li>
<li>TEVA dilTIAZem XC;</li>
<li>TEVA-Diltazem [DSC];</li>
<li>TEVA-Diltiazem CD;</li>
<li>TEVA-Diltiazem HCl ER;</li>
<li>Tiazac;</li>
<li>Tiazac XC</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F160711"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antianginal Agent;</li>
<li>
                        Antiarrhythmic Agent, Class IV;</li>
<li>
                        Antihypertensive;</li>
<li>
                        Calcium Channel Blocker;</li>
<li>
                        Calcium Channel Blocker, Nondihydropyridine</li></ul></div>
<div class="block doa drugH1Div" id="F160662"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety: </b>Avoid in patients taking a beta-blocker or who have heart failure with reduced ejection fraction, sinus node dysfunction, or second- or third-degree atrioventricular block unless a functioning pacemaker has been placed.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c263a8d4-f2ef-49a8-a963-6b87a475dbec">Angina</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Chronic stable angina (alternative agent):</i> Note:</b> A beta-blocker is the preferred initial therapy; if there are ongoing symptoms on beta-blocker therapy, a calcium channel blocker (typically a dihydropyridine [eg, amlodipine]) may be added with close monitoring of heart rate; diltiazem may be used as an alternative therapy if there are contraindications or unacceptable adverse effects with beta-blockade (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i>
<b>Oral: </b>Initial: 30 mg 4 times daily; increase as needed at 1- to 2-day intervals to effective antianginal dose; usual effective dose: 240 to 360 mg/day in 3 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kannam.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kannam.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>12-hour (twice-daily) formulations (off label): </i>
<b>Oral: </b>Initial: 60 mg twice daily; increase as needed at 7- to 14-day intervals to effective antianginal dose; usual effective dose: 240 to 360 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kannam.2019','lexi-content-ref-3510525']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kannam.2019','lexi-content-ref-3510525'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>24-hour (once-daily) formulations:</i>
<b>Oral: </b>Initial 120 to 180 mg once daily; increase as needed at 7- to 14-day intervals to effective antianginal dose; usual effective dose: 240 to 360 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kannam.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kannam.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Vasospastic angina:</b></i>
<b>Note:</b> May use alone or in combination with nitrates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23166211']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23166211'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i>
<b>Oral: </b>Initial: 30 mg 4 times daily; increase as needed at 1- to 2-day intervals to effective antianginal dose; usual effective dose: 240 to 360 mg/day in 3 to 4 divided doses.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>12-hour (twice-daily) formulations (off label): </i>
<b>Oral: </b>Initial: 60 mg twice daily; increase as needed at 7- to 14-day intervals to effective antianginal dose; usual effective dose: 240 to 360 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pinto.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pinto.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>24-hour (once-daily) formulations: </i>
<b>Oral: </b>Initial: 120 to 180 mg once daily; increase as needed at 7- to 14-day intervals to effective antianginal dose; usual effective dose: 240 to 360 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pinto.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pinto.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Chest pain associated with cocaine ingestion, with or without evidence of acute coronary syndrome (off-label use)</i></b>
<i>: </i>
<b>Note:</b> Adjunct or alternative to nitroglycerin.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Bolus: Initial: 0.25 mg/kg (actual body weight) over 2 minutes (average dose: 20 mg); may repeat after 15 minutes if needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Moragan.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Moragan.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0156d4e3-c53d-4d3c-809d-02d27775d840">Atrial fibrillation/flutter, rate control</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation/flutter, rate control: Note: </b>For rate control in hemodynamically stable patients. Do <b>not</b> use in patients with preexcitation associated with an accessory pathway, as this can lead to ventricular arrhythmias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24685669']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24685669'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Acute ventricular rate control:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Bolus dose: 0.25 mg/kg (actual body weight) over 2 minutes (average dose: 20 mg; if hypotension is a concern, some experts administer a lower bolus of 5 to 15 mg); if rate control is insufficient after 15 minutes, a repeat bolus dose of 0.35 mg/kg over 2 minutes may be given (average dose: 25 mg). Patients who respond after 1 or 2 bolus doses can be started on a continuous infusion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ganz.2019','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ganz.2019','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Continuous infusion following bolus(es): Initial: 5 to 10 mg/hour; infusion rate may be increased in 5 mg/hour increments according to ventricular response, up to a maximum of 15 mg/hour. <b>Note: </b>When increasing the infusion rate, an additional bolus dose can be used to provide more immediate onset. In general, the use of a continuous infusion &gt;24 hours or &gt;15 mg/hour is not recommended due to potential for drug accumulation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1894861','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1894861','lexi-content-ref-Manu.1'])">Ref</a></span>). See conversion section below to switch from IV infusion to oral.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Chronic ventricular rate control (off-label use):</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i>
<b>Oral: </b>Initial: 30 mg 4 times daily; increase as needed to achieve ventricular rate control; usual dose: 120 to 480 mg/day in 3 or 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ganz.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ganz.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release: </i>
<b>Oral: </b>Initial: 120 mg once daily or in 2 divided doses depending on formulation; increase as needed to achieve ventricular rate control; usual dose: 120 to 480 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24685669','lexi-content-ref-Ganz.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24685669','lexi-content-ref-Ganz.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension (alternative agent): </b>
<b>Note</b>
<b>:</b> Reserve nondihydropyridine calcium channel blockers for patients with a relevant comorbidity (eg, rate control in atrial fibrillation or flutter) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Mann.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Mann.2019'])">Ref</a></span>). For patients who warrant combination therapy (BP &gt;20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use in combination with another appropriate agent (eg, angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, thiazide diuretic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>12-hour (twice-daily) formulations:</i>
<b>Oral: </b>Initial: 60 to 120 mg twice daily; increase dose as needed after ~7 to 14 days; usual dose: 240 to 360 mg/day in 2 divided doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>24-hour (once-daily) formulations:</i>
<b>Oral: </b>Initial: 120 to 240 mg once daily; increase dose as needed after ~7 to 14 days; usual dose: 120 to 360 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c6cc9954-dac7-46ff-8fbb-4fd8de1d9ff9">Nonsustained ventricular tachycardia or ventricular premature beats, symptomatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonsustained ventricular tachycardia or ventricular premature beats, symptomatic (alternative agent) (off-label use): Note:</b> A beta-blocker is the preferred initial therapy; if there are ongoing symptoms on beta-blocker therapy, diltiazem may be added with close monitoring of heart rate; diltiazem may be used as an alternative therapy if beta-blockade cannot be tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manolis.2019','lexi-content-ref-Zimetbaum.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manolis.2019','lexi-content-ref-Zimetbaum.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 120 to 180 mg once daily or in divided doses depending on the drug formulation; usual effective dose: 240 to 360 mg/day; maximum dose: 480 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manolis.2019','lexi-content-ref-Zimetbaum.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manolis.2019','lexi-content-ref-Zimetbaum.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3148a3ba-0ac4-46a3-b3b8-7e0b78bd77a6">Pulmonary arterial hypertension, group 1</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pulmonary arterial hypertension, group 1 </b>
<b>(alternative agent) (off-label use): Note:</b> Only used for group 1 pulmonary arterial hypertension patients with a positive vasoreactivity test and under the care of a pulmonary hypertension specialist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30660783','lexi-content-ref-36017548']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30660783','lexi-content-ref-36017548'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>12-hour (twice-daily) formulations: </i>
<b>Oral: </b>Initial: 60 mg every 12 hours; titrate gradually, with close hemodynamic monitoring; reported daily dose range: 120 to 720 mg/day in 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30660783','lexi-content-ref-36017548','lexi-content-ref-20543192','lexi-content-ref-15939821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30660783','lexi-content-ref-36017548','lexi-content-ref-20543192','lexi-content-ref-15939821'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>24-hour (once-daily) formulations:</i>
<b>Oral:</b> Initial: 120 mg once daily; titrate gradually, with close hemodynamic monitoring; reported daily dose range: 120 to 720 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30660783','lexi-content-ref-36017548','lexi-content-ref-20543192','lexi-content-ref-15939821']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30660783','lexi-content-ref-36017548','lexi-content-ref-20543192','lexi-content-ref-15939821'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f882e79-d62c-4b63-bf32-63cd49609f40">Supraventricular tachycardia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Supraventricular tachycardia (eg, atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, focal atrial tachycardia, multifocal atrial tachycardia) (alternative agent): Note: </b>For hemodynamically stable patients if vagal maneuvers and/or adenosine are unsuccessful. Do <b>not</b> use in patients with preexcitation associated with an accessory pathway, as this can lead to ventricular arrhythmias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26399663','lexi-content-ref-Prutkin.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26399663','lexi-content-ref-Prutkin.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Acute treatment:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Bolus dose: 0.25 mg/kg (actual body weight) over 2 minutes (average dose: 20 mg); if response is insufficient after ≥15 minutes, a repeat bolus dose of 0.35 mg/kg over 2 minutes may be given (average dose: 25 mg). If bolus(es) do not terminate the arrhythmia, consider alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Chronic maintenance (off-label use): </i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i>
<b>Oral:</b> Initial: 30 mg 4 times daily; increase as needed for heart rate control; usual effective dose: 360 mg/day in divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26399663']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26399663'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release:</i>
<b>Oral:</b> Initial: 120 mg once daily or in 2 divided doses depending on formulation; increase as needed for heart rate control; usual effective dose: 360 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26399663']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26399663'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Conversion between dosage forms:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Conversion from immediate-release to extended-release formulations:</i></b> Patients stabilized on a maintenance regimen between 120 and 360 mg of immediate-release tablets may be switched to an extended-release formulation at the same daily dose administered in 1 or 2 divided doses depending on formulation. In some patients, the dosage of the extended-release formulation may require adjustment following conversion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Conversion from IV infusion to oral:</i></b> Immediate release can be started ~1 hour before stopping infusion. Oral daily dose may be <b>estimated</b> from the IV infusion rate by using the equation below. Round oral doses to the nearest appropriate strength and formulation.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral dose (mg per day) = [infusion rate (mg/hour) × 3 + 3] × 10</p>
<p style="text-indent:-2em;margin-left:8em;">5 mg/hour = 180 mg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">10 mg/hour = 300 to 360 mg/day.</p>
<p style="text-indent:-2em;margin-left:8em;">15 mg/hour = 480 mg/day.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991791"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3542336','lexi-content-ref-6873142','lexi-content-ref-2031991','lexi-content-ref-2031997']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3542336','lexi-content-ref-6873142','lexi-content-ref-2031991','lexi-content-ref-2031997'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12589171']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12589171'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not significantly dialyzed: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3392246']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3392246'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988980"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution; extensively metabolized by the liver; half-life is increased in patients with cirrhosis.</p></div>
<div class="block doe drugH1Div" id="F160663"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. In the management of hypertension, consider lower initial doses (eg, 120 mg once daily using extended-release capsule) and titrate to response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21518977']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21518977'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F160686"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13233" href="/d/html/13233.html" rel="external">see "Diltiazem: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ad1bb51c-8e67-4d19-8dfb-85a719d71adc">Atrial tachyarrhythmias, rate control</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial tachyarrhythmias, rate control (bridge to therapy):</b> Very limited data available: Infants ≥6 months, Children, and Adolescents: IV: Initial bolus: 0.25 mg/kg over 5 minutes (maximum dose: 20 mg/dose [average adult dose]) followed by a continuous IV infusion; reported rate range in one study was 0.05 to 0.15 mg/kg/hour. <b>Note</b>: Usual adult infusion rate for arrhythmia is 5 to 15 mg/hour. Dose should be individualized based on patient response. Dosing based on a small study of 10 patients with atrial tachycardia (age range: 6 months to 21 years; most patients were adolescents) who received an initial bolus of 0.25 mg/kg/dose followed by a continuous infusion titrated to effect, reported effective range was 0.05 to 0.15 mg/kg/hour (mean infusion rate: 0.11 mg/kg/hour). Rate control was achieved in 9 of the 10 patients within 10 minutes of dosing. One patient required an additional bolus of 0.25 mg/kg. Median ventricular rate of study group prior to initial bolus was 275 ± 50 beats per minute (BPM) (range: 185 to 500 BPM), which decreased to a median of 166 BPM prior to initiation of continuous infusion and decreased to a median of 123 BPM after 10 minutes of continuous infusion; blood pressure was not significantly affected by diltiazem; qualitative systolic function did not worsen in the seven patients studied (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11009280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11009280'])">Ref</a></span>). <b>Note:</b> In adult patients, infusions &gt;24 hours are not recommended; with administration of diltiazem infusion &gt;24 hours, the possibility of decreased diltiazem clearance, prolonged elimination half-life, and increased diltiazem and/or diltiazem metabolite plasma concentrations should be considered. In trial of 10 pediatric patients, the median duration was 45 hours (mean: 54 hours; range: 14 to 126 hours) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11009280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11009280'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children: Oral: <i>Immediate-release formulations</i>: Initial: 1.5 to 2 mg/kg/day in 3 to 4 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11149130','lexi-content-ref-Park.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11149130','lexi-content-ref-Park.2014'])">Ref</a></span>); increase gradually, at 1- to 2-day intervals until optimum response is obtained; usual maximum daily dose: 3.5 mg/kg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.2014'])">Ref</a></span>); some experts recommend a higher maximum daily dose of 6 mg/kg/<b>day</b> up to 360 mg/<b>day</b>; whichever is less (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11149130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11149130'])">Ref</a></span>). <b>Note:</b> Once patient is established on a total daily dose, may convert to an extended release dosage form at the appropriate interval (once or twice daily) in children able to swallow capsules whole and receiving adequate mg amount (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11149130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11149130'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Park.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Park.2014'])">Ref</a></span>): Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate-release formulations</i>: 30 to 120 mg/dose administered 3 to 4 times daily; usual daily dosage range: 180 to 360 mg/day</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended-release formulations:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Capsule, extended release (once daily dosing; eg, Cardizem CD, Tiazac): 120 to 300 mg once daily</p>
<p style="text-indent:-2em;margin-left:8em;">Capsule, extended release (twice daily dosing; eg, Cardizem SR): 120 to 300 mg/day in 2 divided doses</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109244"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Dialysis: Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.</p></div>
<div class="block dohp drugH1Div" id="F51109245"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustment provided in the manufacturer’s labeling; use with caution; extensively metabolized by the liver; half-life is increased in patients with cirrhosis.</p></div>
<div class="block arsc drugH1Div" id="F54448468"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bradyarrhythmias</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Diltiazem may cause <b>first-degree atrioventricular </b>(AV)<b> block</b>, <b>second-degree atrioventricular block</b>, <b>complete atrioventricular block</b>, or sinus <b>bradycardia</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3943233','lexi-content-ref-8879597','lexi-content-ref-33391915','lexi-content-ref-22530749','lexi-content-ref-2564139']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3943233','lexi-content-ref-8879597','lexi-content-ref-33391915','lexi-content-ref-22530749','lexi-content-ref-2564139'])">Ref</a></span>). Although reversal is possible after discontinuation, some patients continue to have symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23878619','lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23878619','lexi-content-ref-15234417'])">Ref</a></span>). In patients whose symptoms resolve after discontinuation, permanent pacemaker (PPM) therapy will likely not be necessary; however, cases with recurrent or unresolved symptoms after discontinuation may warrant PPM placement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15234417']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15234417'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Related to the pharmacologic action; inhibits L-type calcium channels, leading to prolonged refractoriness and slowing of AV nodal conduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7110278','lexi-content-ref-3943233','lexi-content-ref-6621654','lexi-content-ref-2450898','lexi-content-ref-1674455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7110278','lexi-content-ref-3943233','lexi-content-ref-6621654','lexi-content-ref-2450898','lexi-content-ref-1674455'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; may occur at any time during therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1674455']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1674455'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concurrent use of other AV nodal-blocking agents (eg, beta-blockers) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8249821','lexi-content-ref-10774785','lexi-content-ref-8879597','lexi-content-ref-22530749','lexi-content-ref-2564139']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8249821','lexi-content-ref-10774785','lexi-content-ref-8879597','lexi-content-ref-22530749','lexi-content-ref-2564139'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8013508','lexi-content-ref-23847692']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8013508','lexi-content-ref-23847692'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8013508','lexi-content-ref-23847692']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8013508','lexi-content-ref-23847692'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Underlying AV node dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23878619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23878619'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cutaneous hypersensitivity reactions</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Diltiazem may cause cutaneous hypersensitivity reactions.<b> Maculopapular rash</b> is the most common cutaneous adverse reaction reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14616146','lexi-content-ref-16045866','lexi-content-ref-8340532']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14616146','lexi-content-ref-16045866','lexi-content-ref-8340532'])">Ref</a></span>). Severe cutaneous adverse reactions (SCARs), including <b>Stevens-Johnson syndrome</b> (SJS), <b>toxic epidermal necrolysis</b> (TEN), drug rash with eosinophilia and systemic symptoms, and <b>acute generalized exanthematous pustulosis</b> (AGEP) have occurred rarely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16778429','lexi-content-ref-9486675','lexi-content-ref-8096307','lexi-content-ref-2292178','lexi-content-ref-9415262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16778429','lexi-content-ref-9486675','lexi-content-ref-8096307','lexi-content-ref-2292178','lexi-content-ref-9415262'])">Ref</a></span>). In general, improvement is observed 1 to 2 weeks after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16045866']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16045866'])">Ref</a></span>). Other cutaneous reactions associated with diltiazem include subacute <b>cutaneous lupus erythematosus</b>, <b>erythema multiforme</b>, erythroderma, <b>exfoliative dermatitis</b>, and <b>hypersensitivity angiitis </b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7477141','lexi-content-ref-16045866','lexi-content-ref-3211830','lexi-content-ref-8365158','lexi-content-ref-25268343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7477141','lexi-content-ref-16045866','lexi-content-ref-3211830','lexi-content-ref-8365158','lexi-content-ref-25268343'])">Ref</a></span>). In comparison to other calcium channel blockers, diltiazem has been associated with more reports of cutaneous reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14616146','lexi-content-ref-2523214','lexi-content-ref-25268343']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14616146','lexi-content-ref-2523214','lexi-content-ref-25268343'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin hyperpigmentation</b>, often in a photodistributed pattern, has also been associated with diltiazem; may present as reticulated, brown, slate-gray, or gray-blue macules or patches most commonly on the face, neck, forearms, and chest (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23846341','lexi-content-ref-20883365','lexi-content-ref-16490848']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23846341','lexi-content-ref-20883365','lexi-content-ref-16490848'])">Ref</a></span>). Gradual improvement is observed after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20883365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20883365'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Delayed hypersensitivity reactions (including SCARs): Non–dose-related; immunologic. Type IV immune-mediated (T-cell mediated) hypersensitivity reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31020549','lexi-content-ref-16778429']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31020549','lexi-content-ref-16778429'])">Ref</a></span>). Skin hyperpigmentation: Not clearly established (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20883365']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20883365'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; maculopapular rashes usually occur within 10 days after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14616146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14616146'])">Ref</a></span>). SCARs usually occur between 1 to 8 weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30028512','lexi-content-ref-9486675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30028512','lexi-content-ref-9486675'])">Ref</a></span>); although, some cases of SJS/TEN may have a more rapid onset (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8096307']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8096307'])">Ref</a></span>). AGEP usually occurs 1 to 2 weeks after initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9486675','lexi-content-ref-17854366']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9486675','lexi-content-ref-17854366'])">Ref</a></span>). Reports of skin hyperpigmentation range from 3 weeks to 12.5 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23846341','lexi-content-ref-37456398','lexi-content-ref-32226335']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23846341','lexi-content-ref-37456398','lexi-content-ref-32226335'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Prior hypersensitivity reaction to diltiazem. <b>Note: </b>Cross-reactivity between diltiazem and other calcium channel blockers is not well defined. There are limited case reports of cross-reactivity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16045866','lexi-content-ref-27025295']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16045866','lexi-content-ref-27025295'])">Ref</a></span>), but these are inconsistent and may not be distinct reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14616146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14616146'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Skin hyperpigmentation:</p>
<p style="text-indent:-2em;margin-left:8em;">- Extended-release formulations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32226335']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32226335'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Patients with Fitzpatrick phototype V and VI skin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32226335']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32226335'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32226335']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32226335'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">- Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32226335']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32226335'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F160620"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Incidences represent ranges for various dosage forms. Patients with impaired ventricular function and/or conduction abnormalities may have higher incidence of adverse reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Cardiovascular: Peripheral edema (5% to 15%; dose-related)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia (3% to 4%), bundle branch block (&lt;2%), cardiac arrhythmia (1%), complete atrioventricular block (&lt;2%), ECG abnormality (&lt;2%), edema (2% to 3%), extrasystoles (2%), first-degree atrioventricular block (3% to 4%), heart failure (&lt;2%), hypotension (3% to 4%), lower extremity edema (5% to 8%), palpitations (1% to 2%), second-degree atrioventricular block (&lt;2%), syncope (&lt;2%), vasodilation (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (&lt;2%), skin photosensitivity (&lt;2%) (Ramirez 2007), skin rash (1% to 2%) (Tuchinda 2014)<span class="lexi-table-link-container"> (<a aria-label="Diltiazem: Adverse Reaction: Skin Rash table link" class="lexi-table-link" data-table-id="lexi-content-diltiazem-adverse-reaction-skin-rash" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-diltiazem-adverse-reaction-skin-rash')">table 1</a>)</span><span class="table-link" style="display:none;">Diltiazem: Adverse Reaction: Skin Rash</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Diltiazem: Adverse Reaction: Skin Rash" frame="border" id="lexi-content-diltiazem-adverse-reaction-skin-rash" rules="all">
<caption style="text-align:center;">
<b>Diltiazem: Adverse Reaction: Skin Rash</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Diltiazem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Diltiazem)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">540 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">49</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Up to 360 mg</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">158</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Albuminuria (&lt;2%), gynecomastia (&lt;2%), hyperglycemia (&lt;2%), hyperuricemia (&lt;2%), increased lactate dehydrogenase (&lt;2%), increased thirst (&lt;2%), weight gain (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal swelling (2%), anorexia (&lt;2%), constipation (&lt;2%), diarrhea (1% to 2%), dysgeusia (&lt;2%), dyspepsia (1% to 6%), nausea (2%), vomiting (&lt;2%), xerostomia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Crystalluria (&lt;2%), erectile dysfunction (2%), nocturia (&lt;2%), polyuria (&lt;2%), sexual difficulty (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Petechia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase (&lt;2%), increased serum alkaline phosphatase (&lt;2%), increased serum aspartate transaminase (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (1% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Burning sensation at injection site (≤4%), injection-site pruritus (≤4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (&lt;2%), abnormal gait (&lt;2%), amnesia (&lt;2%), asthenia (1% to 4%), depression (&lt;2%), dizziness (2% to 10%), drowsiness (&lt;2%), fatigue (5%), hallucination (&lt;2%), headache (2% to 8%), insomnia (&lt;2%), nervousness (2%), pain (6%), paresthesia (&lt;2%), personality changes (&lt;2%), tremor (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Gout (1% to 2%), increased creatine phosphokinase in blood specimen (&lt;2%), muscle cramps (&lt;2%), myalgia (2%), neck stiffness (&lt;2%), osteoarthritis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia (&lt;2%), conjunctivitis (2%), eye irritation (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis (1% to 4%), cough (1% to 2%), dyspnea (1% to 6%), epistaxis (&lt;2%), flu-like symptoms (2%), paranasal sinus congestion (1% to 2%), pharyngitis (6%), rhinitis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial flutter, sinus node dysfunction, ventricular fibrillation, ventricular tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Hepatic: Hepatic injury (Deng 2013; Shallcross 1987), increased serum bilirubin</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Asystole (Moser 1996; Subahi 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis (Gesierich 2006; Knowles 1998; Sáenz de Santa María García 2016; Vicente-Calleja 1997), alopecia, cutaneous lupus erythematosus (Crowson 1995; Srivastava 2003), erythema multiforme (Stern 1989; Wittal 1992), exfoliative dermatitis (Odeh 1997; Sousa-Basto 1993), maculopapular rash (Cholez 2003; Gonzalo Garijo 2005), psoriasis (Song 2021), skin hyperpigmentation (Siegel 2020), Stevens-Johnson syndrome (Sanders 1993; Taylor 1990), toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Gingival hyperplasia (Bowman 1988; Steele 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemolytic anemia, leukopenia, prolonged bleeding time, purpuric disease (Inui 2001), thrombocytopenia (Michalets 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema, hypersensitivity angiitis (Sheehan-Dare 1988)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Extrapyramidal reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myopathy (Ahmad 1993)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Periorbital edema (Friedland 1993), retinopathy</p></div>
<div class="block coi drugH1Div" id="F160636"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Hypersensitivity to diltiazem or any component of the formulation; sick sinus syndrome (except in patients with a functioning artificial pacemaker); second- or third-degree AV block (except in patients with a functioning artificial pacemaker); hypotension (systolic &lt;90 mm Hg); acute MI and pulmonary congestion</p>
<p style="text-indent:-2em;margin-left:2em;">Intravenous (IV): Hypersensitivity to diltiazem or any component of the formulation; sick sinus syndrome (except in patients with a functioning artificial pacemaker); second- or third-degree AV block (except in patients with a functioning artificial pacemaker); severe hypotension; cardiogenic shock; administration concomitantly or within a few hours of the administration of IV beta-blockers; atrial fibrillation or flutter associated with accessory bypass tract (eg, Wolff-Parkinson-White syndrome, short PR syndrome); ventricular tachycardia (with wide-complex tachycardia [QRS ≥0.12 seconds], must determine whether origin is supraventricular or ventricular)</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy; use in women of childbearing potential; breastfeeding; concurrent use with IV dantrolene, ivabradine, or lomitapide; severe bradycardia (&lt;40 beats per minute).</p></div>
<div class="block war drugH1Div" id="F160617"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Mild elevations of transaminases with and without concomitant elevation in alkaline phosphatase and bilirubin have been observed and frequently resolve spontaneously. Significant elevations in hepatic transaminases (eg, alkaline phosphatase, LDH, AST, ALT) and signs of acute hepatic injury have also been observed 1 to 8 weeks after therapy initiation and have been reversible upon discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Accessory bypass tract (eg, Wolff-Parkinson-White [WPW] syndrome): During an episode of atrial fibrillation or flutter in patients with an accessory bypass tract or preexcitation syndrome, use has been associated with increased anterograde conduction down the accessory pathway leading to ventricular fibrillation; avoid use in such patients (ACLS [Neumar 2010]; AHA/ACC/HRS [January 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Left ventricular dysfunction: Use with caution in left ventricular dysfunction; due to negative inotropic effects, may exacerbate condition. Avoid use in patients with heart failure due to lack of benefit and/or worse outcomes with calcium channel blockers in general (AHA/ACC/HFSA [Heidenreich 2022]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: IV: Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of IV diltiazem. Use with caution in patients hemodynamically compromised; continuously monitor ECG and blood pressure during administration (especially during continuous IV infusion). Initial use should be, if possible, in a setting where monitoring and resuscitation equipment, including DC cardioversion/defibrillation, are present.</p></div>
<div class="block foc drugH1Div" id="F160628"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 12 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 60 mg, 90 mg, 120 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardizem CD: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cartia XT: 120 mg, 180 mg, 240 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cartia XT: 300 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40 (allura red ac dye), fd&amp;c red #40(allura red ac)aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Dilt-XR: 120 mg, 180 mg, 240 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Taztia XT: 120 mg [contains corn starch, fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40 (allura red ac dye), fd&amp;c red #40(allura red ac)aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Taztia XT: 180 mg [contains corn starch, fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6 (sunset yellow), quinoline (d&amp;c yellow #10) aluminum lake, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Taztia XT: 240 mg [contains corn starch, fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40 (allura red ac dye), fd&amp;c red #40(allura red ac)aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Taztia XT: 300 mg [contains corn starch, fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40 (allura red ac dye), fd&amp;c red #40(allura red ac)aluminum lake, fd&amp;c yellow #6 (sunset yellow), quinoline (d&amp;c yellow #10) aluminum lake, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Taztia XT: 360 mg [contains corn starch, fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c blue #1 (brilliant blue), fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tiadylt ER: 120 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tiadylt ER: 180 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tiadylt ER: 240 mg, 300 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tiadylt ER: 360 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tiadylt ER: 420 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tiazac: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/5 mL (5 mL); 50 mg/10 mL (10 mL); 125 mg/25 mL (25 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/5 mL (5 mL [DSC]); 50 mg/10 mL (10 mL [DSC]); 125 mg/25 mL (25 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardizem: 30 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardizem: 60 mg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, methylparaben, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardizem: 120 mg [scored; contains fd&amp;c yellow #6(sunset yellow)alumin lake, methylparaben, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg, 60 mg, 90 mg, 120 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardizem LA: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Matzim LA: 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</p></div>
<div class="block geq drugH1Div" id="F160613"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F160638"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Cardizem CD Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $34.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $43.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $58.39</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $76.48</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $111.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Cartia XT Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $1.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $1.45</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $2.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $2.66</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (dilTIAZem HCl ER Beads Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $0.75 - $1.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $0.90 - $1.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $1.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $2.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $2.59</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">420 mg (per each): $1.77 - $2.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (dilTIAZem HCl ER Coated Beads Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $0.91 - $1.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $1.02 - $1.45</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $1.40 - $2.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $1.90 - $2.66</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $9.17 - $10.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (dilTIAZem HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $1.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $1.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $1.43</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Taztia XT Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $1.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $1.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $1.96</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $2.54</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $2.59</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Tiadylt ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $1.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $1.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $1.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $2.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $2.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">420 mg (per each): $2.46</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule ER 24 Hour Therapy Pack</b> (Tiazac Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $2.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $2.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $4.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $5.24</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $5.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">420 mg (per each): $5.60</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, 12-hour</b> (dilTIAZem HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $3.17 - $3.97</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $3.62 - $4.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $4.73 - $6.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (dilTIAZem HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/5 mL (per mL): $0.52 - $0.91</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/10 mL (per mL): $0.48 - $0.83</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mg/25 mL (per mL): $0.28 - $0.53</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (dilTIAZem HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $13.69</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Cardizem LA Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $4.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $4.82</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $5.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $7.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $7.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">420 mg (per each): $8.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (dilTIAZem HCl ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $2.82 - $4.10</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $2.86 - $2.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $3.20 - $3.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $4.16 - $4.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $4.48 - $4.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">420 mg (per each): $4.85 - $5.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Matzim LA Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">180 mg (per each): $2.98</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">240 mg (per each): $3.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">300 mg (per each): $4.34</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">360 mg (per each): $4.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">420 mg (per each): $5.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Cardizem Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $7.68</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $12.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $22.18</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (dilTIAZem HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $1.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $1.57</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">90 mg (per each): $2.14</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $2.88</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866606"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardizem CD: 120 mg [DSC], 180 mg [DSC], 240 mg [DSC], 300 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tiazac: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg/mL (5 mL, 10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg, 60 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tiazac XC: 120 mg, 360 mg, 180 mg/24 hr, 240 mg/24 hr, 300 mg/24 hr</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 180 mg, 240 mg, 300 mg, 360 mg</p></div>
<div class="block adm drugH1Div" id="F160632"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">IR tablet (eg, Cardizem): Administer before meals and at bedtime. Tablets may be swallowed whole, crushed, or chewed; do not split nonscored tablets.</p>
<p style="text-indent:-2em;margin-left:4em;">Long-acting dosage forms: Do not open, chew, or crush; swallow whole. Administer at same time of day either morning or evening.</p>
<p style="text-indent:-2em;margin-left:6em;">Cardizem CD, Cardizem LA, Cartia XT, Matzim LA: Administer without regard to meals.</p>
<p style="text-indent:-2em;margin-left:6em;">Dilt-XR: Administer on an empty stomach in the morning.</p>
<p style="text-indent:-2em;margin-left:6em;">Taztia XT, Tiazac: Capsules may be opened and sprinkled on a spoonful of applesauce. Applesauce should not be hot and should be swallowed without chewing, followed by drinking a glass of water.</p>
<p style="text-indent:-2em;margin-left:6em;">Tiazac XC [Canadian product]: Administer at bedtime.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Capsule and tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Tiazac or generic equivalent capsule may be opened and contents sprinkled onto soft food of choice. Other ER formulations, such as Cardizem CD, LA, SR or generic equivalents have no data on opening capsule. Dilacor XR or generic equivalent manufacturers say do not open capsule.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Bolus doses given over 2 minutes with continuous ECG and blood pressure monitoring. Continuous infusion should be via infusion pump. May increase infusion rate in 5 mg/hour increments as needed (maximum: 15 mg/hour). Response to bolus may require several minutes to reach maximum. Response may persist for several hours after infusion is discontinued.</p></div>
<div class="block admp drugH1Div" id="F52612575"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet, immediate release (eg, Cardizem): Administer before meals and at bedtime. Tablets may be swallowed whole, crushed, or chewed; scored tablets may be split.</p>
<p style="text-indent:-2em;margin-left:4em;">Extended-release preparations: Swallow whole; do not chew, break, or crush. Administer at the same time of day, either morning or evening.</p>
<p style="text-indent:-2em;margin-left:6em;">Cardizem CD, Cardizem LA, Cartia XT, Matzim LA: May be administered with or without food, but should be administered consistently with relation to meals; administer with a full glass of water.</p>
<p style="text-indent:-2em;margin-left:6em;">Taztia XT and Tiazac: Capsules may be opened and sprinkled on applesauce; swallow applesauce immediately, do not chew; follow with some cool water (adults: 1 glass) to ensure complete swallowing; do not use hot applesauce; do not divide capsule contents (ie, do not administer partial doses); do not store mixture of applesauce and capsule contents, use immediately.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:4em;">IV bolus: Pediatric patients ≥6 months of age: Administration over 5 minutes at a concentration ≤5 mg/mL with continuous ECG monitoring has been used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11009280']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11009280'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Continuous IV infusion: Administer as a continuous IV infusion with the use of an infusion pump with continuous ECG monitoring. Response may persist for several hours after infusion is discontinued.</p></div>
<div class="block uica drugH1Div" id="F14471309"><span class="drugH1">Usual Infusion Concentrations: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV infusion:</b> 125 mg in 125 mL (total volume) (concentration: 1 mg/mL) of D<sub>5</sub>W or  NS</p></div>
<div class="block use drugH1Div" id="F160631"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Hypertension, chronic stable angina, vasospastic angina</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Injection:</b> Atrial fibrillation or atrial flutter for acute ventricular rate control, conversion of supraventricular tachycardia</p></div>
<div class="block off-label drugH1Div" id="F25475027"><span class="drugH1">Use: Off-Label: Adult</span><p>Atrial fibrillation or atrial flutter, chronic ventricular rate control; Chest pain associated with cocaine ingestion, with or without evidence of acute coronary syndrome; Hypertrophic cardiomyopathy; Idiopathic ventricular tachycardia; Nonsustained ventricular tachycardia or ventricular premature beats, symptomatic; Pulmonary arterial hypertension, group 1; Supraventricular tachycardia (eg, atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia, focal atrial tachycardia, multifocal atrial tachycardia)</p></div>
<div class="block mst drugH1Div" id="F160720"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cardizem may be confused with Cardene, Cardene SR, Cardizem CD, Cardizem SR, cortisone</p>
<p style="text-indent:-2em;margin-left:4em;">Cartia XT may be confused with Procardia XL</p>
<p style="text-indent:-2em;margin-left:4em;">DilTIAZem may be confused with Calan, diazePAM, Dilantin</p>
<p style="text-indent:-2em;margin-left:4em;">Tiazac may be confused with Tigan, Tiazac XC [CAN], Ziac</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication (IV formulation) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cardizem [US, Canada, and multiple international markets] may be confused with Cardem brand name for celiprolol [Spain]</p>
<p style="text-indent:-2em;margin-left:4em;">Cartia XT [US] may be confused with Cartia brand name for aspirin [multiple international markets]</p>
<p style="text-indent:-2em;margin-left:4em;">Dipen [Greece] may be confused with Depen brand name for penicillamine [US]; Depin brand name for nifedipine [India]; Depon brand name for acetaminophen [Greece]</p>
<p style="text-indent:-2em;margin-left:4em;">Tiazac: Brand name for dilTIAZem [US, Canada], but also the brand name for pioglitazone [Chile]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F160705"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (weak), CYP3A4 (moderate)</p></div>
<div class="block dri drugH1Div" id="F160622"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Abemaciclib.  Management: Monitor for increased abemaciclib toxicities if combined with moderate CYP3A4 inhibitors. Consider reducing the abemaciclib dose in 50 mg decrements if necessary.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Acalabrutinib.  Management: Reduce acalabrutinib dose to 100 mg once daily with concurrent use of a moderate CYP3A4 inhibitor. Monitor patient closely for both acalabrutinib response and evidence of adverse effects with any concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALfentanil.  Management: If use of alfentanil and moderate CYP3A4 inhibitors is necessary, consider dosage reduction of alfentanil until stable drug effects are achieved. Frequently monitor patients for respiratory depression and sedation when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alfuzosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alitretinoin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Alitretinoin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ALPRAZolam.  Management: Consider alternatives to this combination when possible. If combined, consider an alprazolam dose reduction and monitor for increased alprazolam effects and toxicities (eg, sedation, lethargy).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Apixaban. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: Calcium Channel Blockers (Nondihydropyridine) may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Astemizole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Astemizole.  Management: Avoid concomitant use of astemizole and moderate CYP3A4 inhibitors whenever possible. If combined, monitor closely for increased astemizole toxicities, especially for QTc interval prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atazanavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atogepant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avacopan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor. Patients receiving such a combination should also be monitored more closely for evidence of adverse effects (eg, hypotension, syncope, priapism).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avapritinib.  Management: Avoid use of moderate CYP3A4 inhibitors with avapritinib. If this combination cannot be avoided, reduce the avapritinib dose to 100 mg daily for the treatment of GIST or to 50 mg daily for the treatment of advanced systemic mastocytosis.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Axitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Barnidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bedaquiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Benzhydrocodone. Specifically, the concentration of hydrocodone may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Blonanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Blonanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: The brexpiprazole dose should be reduced to 25% of usual if used together with both a moderate CYP3A4 inhibitor and a strong or moderate CYP2D6 inhibitor, or if a moderate CYP3A4 inhibitor is used in a CYP2D6 poor metabolizer.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inhibitors when possible. If such a combination cannot be avoided, reduce the dose of brigatinib by approximately 40% (ie, from 180 mg to 120 mg, from 120 mg to 90 mg, or from 90 mg to 60 mg).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bromocriptine.  Management: The bromocriptine dose should not exceed 1.6 mg daily with use of a moderate CYP3A4 inhibitor. The Cycloset brand specifically recommends this dose limitation, but other bromocriptine products do not make such specific recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic).  Management: Avoid the concomitant use of CYP3A4 inhibitors and oral budesonide. If patients receive both budesonide and CYP3A4 inhibitors, they should be closely monitored for signs and symptoms of corticosteroid excess.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Topical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Capivasertib.  Management: If capivasertib is combined with moderate CYP3A4 inhibitors, reduce the capivasertib dose to 320 mg twice daily for 4 days, followed by 3 days off. Monitor patients closely for adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine).  Management: Consider alternatives to this combination when possible. If combined, monitor for increased carbamazepine concentrations and toxicities and monitor for decreased calcium channel blocker efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Cardiac Glycosides. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Cariprazine. Specifically, concentrations of didesmethylcariprazine (DDCAR), the primary active metabolite of cariprazine, may increase. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cariprazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cilostazol.  Management: Decrease the dose of cilostazol to 50 mg twice daily when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cisapride: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cisapride.  Management: Consider alternatives to this combination. Prescribing information for some moderate CYP3A4 inhibitors state coadministration with cisapride is contraindicated, while some others recommend monitoring and dose titration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Cobimetinib.  Management: Avoid this combination when possible. If concurrent short term (14 days or less) use cannot be avoided, reduce the cobimetinib dose from 60 mg to 20 mg daily. Avoid concomitant use in patients already receiving reduced cobimetinib doses.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Avoidance, dose reduction, or increased monitoring for colchicine toxicity may be needed and will depend on brand, indication for colchicine use, renal/hepatic function, and use of a P-gp inhibitor. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Conivaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Conivaptan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Crizotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of DilTIAZem.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of DilTIAZem. Management: Consider alternatives to this combination when possible. If combined, monitor for decreased diltiazem efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of DilTIAZem.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of DilTIAZem.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabrafenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers. Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dapoxetine.  Management: The dose of dapoxetine should be limited to 30 mg per day when used together with a moderate inhibitor of CYP3A4.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Daridorexant.  Management: Limit the daridorexant dose to 25 mg, no more than once per night, when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Darifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dasatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deflazacort.  Management: Administer one third of the recommended deflazacort dose when used together with a strong or moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delamanid: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Delamanid. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOCEtaxel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOCEtaxel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dofetilide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Domperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Domperidone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Dronedarone. Other electrophysiologic effects of Dronedarone may also be increased. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Dronedarone. Dronedarone may increase the serum concentration of Calcium Channel Blockers (Nondihydropyridine).  Management: Use lower starting doses of the nondihydropyridine calcium channel blockers and only increase calcium channel blocker dose after obtaining ECG-based evidence that the combination is being well-tolerated. Monitor closely during coadministration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ebastine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ebastine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elbasvir and Grazoprevir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eletriptan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor.  Management: When combined with moderate CYP3A4 inhibitors, elexacaftor/tezacaftor/ivacaftor should be given in the morning, every other day. Ivacaftor alone should be given in the morning, every other day on alternate days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Reduce eliglustat dose to 84 mg daily in CYP2D6 EMs when used with moderate CYP3A4 inhibitors. Avoid use of moderate CYP3A4 inhibitors in CYP2D6 IMs or PMs. Use in CYP2D6 EMs or IMs also taking strong or moderate CYP2D6 inhibitors is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: DilTIAZem may increase the serum concentration of Encorafenib. Encorafenib may decrease the serum concentration of DilTIAZem.  Management: Avoid use of encorafenib and diltiazem when possible. If combined, decrease the encorafenib dose from 450 mg to 225 mg; 300 mg to 150 mg; and 225 mg or 150 mg to 75 mg. Monitor for reduced diltiazem efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Entrectinib.  Management: Avoid moderate CYP3A4 inhibitors if possible. If needed, reduce entrectinib dose to 50 mg/day if starting dose 200 mg; to 100 mg/day if starting dose 300 mg; to 200 mg if starting dose 400 mg or 600 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: If coadministered with moderate CYP3A4 inhibitors, the max dose of eplerenone is 25 mg daily if used for heart failure; if used for hypertension initiate eplerenone 25 mg daily, titrate to max 25 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May increase the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Erythromycin (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esmolol: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Esmolol.  Management: Administration of IV verapamil or diltiazem together with esmolol is contraindicated if one agent is given while the effects of the other are still present. Canadian esmolol labeling specifies that use within 24 hours is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eszopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eszopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fedratinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Consider fentanyl dose reductions when combined with a moderate CYP3A4 inhibitor. Monitor for respiratory depression and sedation. Upon discontinuation of a CYP3A4 inhibitor, consider a fentanyl dose increase; monitor for signs and symptoms of withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Flibanserin.  Management: Use of flibanserin with moderate CYP3A4 inhibitors is contraindicated. If starting flibanserin, start 2 weeks after the last dose of the CYP3A4 inhibitor. If starting a CYP3A4 inhibitor, start 2 days after the last dose of flibanserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Nasal): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fluticasone (Oral Inhalation). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosamprenavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Fosaprepitant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine).  Management: Consider alternatives to this combination when possible. If combined, monitor for increased phenytoin concentrations and toxicities and monitor for decreased calcium channel blocker efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gepirone.  Management: Reduce the gepirone dose by 50% if combined with moderate CYP3A4 inhibitors. Monitor for QTc interval prolongation with combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Gilteritinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Glasdegib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of GuanFACINE.  Management: Reduce the extended-release guanfacine dose 50% when combined with a moderate CYP3A4 inhibitor. Monitor for increased guanfacine toxicities when these agents are combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guggul: May decrease the serum concentration of DilTIAZem.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ibrutinib.  Management: When treating B-cell malignancies, decrease ibrutinib to 280 mg daily when combined with moderate CYP3A4 inhibitors. When treating graft versus host disease, monitor patients closely and reduce the ibrutinib dose as needed based on adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Iloperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, the serum concentration of SN-38 may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Irinotecan Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inhibitors (Moderate) may increase isavuconazole serum concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Itraconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Ivacaftor dose reductions may be required; consult full drug interaction monograph content for age- and weight-specific dosage recommendations.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivosidenib.  Management: Avoid use of moderate CYP3A4 inhibitors with ivosidenib whenever possible. If combined, monitor for increased ivosidenib toxicities, including QTc prolongation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Larotrectinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lefamulin.  Management: Monitor for lefamulin adverse effects during coadministration of lefamulin tablets with moderate CYP3A4 inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Leniolisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levoketoconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomilnacipran: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Levomilnacipran. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Lidocaine (Systemic). Specifically, concentrations of monoethylglycinexylidide (MEGX) may be increased. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Calcium Channel Blockers (Nondihydropyridine) may enhance the neurotoxic effect of Lithium. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Lithium. Decreased or unaltered lithium concentrations have also been reported with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lopinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: DilTIAZem may increase the serum concentration of Lovastatin.  Management: Initiate immediate release lovastatin at a dose of 10 mg/day, and do not exceed 20 mg/day for immediate or extended release lovastatin, in patients receiving diltiazem. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lumateperone.  Management: Limit the lumateperone dose to 21 mg once daily when used with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: US labeling recommends reducing lurasidone dose by 50% with a moderate CYP3A4 inhibitor and initiating 20 mg/day, max 80 mg/day. Some non-US labels recommend initiating lurasidone 20 mg/day, max 40 mg/day. Avoid concurrent use of grapefruit products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurbinectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurbinectedin.  Management: Avoid concomitant use of lurbinectedin and moderate CYP3A4 inhibitors when possible. If combined, consider a lurbinectedin dose reduction as clinically indicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Manidipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Manidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Maraviroc. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: Calcium Channel Blockers (Nondihydropyridine) may enhance the adverse/toxic effect of Mavacamten. Specifically, negative inotropic effects may be increased. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Mavacamten.  Management: Start mavacamten at 5 mg/day if stable on a non-DHP CCB. For those stable on mavacamten who are initiating a non-DHP CCB, reduce mavacamten dose by one dose level. Monitor for excessive negative inotropic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Methadone.  Management: If coadministration with moderate CYP3A4 inhibitors is necessary, consider methadone dose reductions until stable effects are achieved. Monitor patients closely for respiratory depression and sedation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methysergide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Methysergide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Midazolam.  Management: Avoid concomitant use of nasal midazolam and moderate CYP3A4 inhibitors. Consider alternatives to use with oral midazolam whenever possible and consider using lower midazolam doses. Monitor patients for sedation and respiratory depression if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: DilTIAZem may increase the serum concentration of Midostaurin.  Management: Seek alternatives to the concomitant use of midostaurin and diltiazem if possible. If concomitant use cannot be avoided, monitor patients for increased risk of adverse reactions.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of MiFEPRIStone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mitapivat.  Management: When coadministered with moderate CYP3A4 inhibitors, doses of mitapivat should not exceed 20 mg twice daily. Additionally, patients should be monitored for changes in hemoglobin response and increased mitapivat adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Mobocertinib.  Management: Avoid use of moderate CYP3A4 inhibitors with mobocertinib when possible. If combined, the mobocertinib dose should be reduced by approximately 50% (ie, from 160 mg to 80 mg, 120 mg to 40 mg, or 80 mg to 40 mg). Monitor QTc interval closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nalfurafine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nalfurafine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Naloxegol.  Management: The use of naloxegol and moderate CYP3A4 inhibitors should be avoided. If concurrent use is unavoidable, reduce naloxegol dose to 12.5 mg once daily and monitor for signs of opiate withdrawal (eg, hyperhidrosis, chills, diarrhea, anxiety, irritability).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Neratinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nilotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Nitrendipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olaparib.  Management: Avoid use of moderate CYP3A4 inhibitors with olaparib, if possible. If such concurrent use cannot be avoided, the dose of olaparib tablets should be reduced to 150 mg twice daily and the dose of olaparib capsules should be reduced to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Omaveloxolone.  Management: Avoid this combination if possible. If coadministration is required, decrease the omaveloxolone dose to 100 mg daily and monitor closely for adverse reactions. If adverse reactions occur, decrease omaveloxolone to 50 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of OxyCODONE. Serum concentrations of the active metabolite Oxymorphone may also be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Palovarotene.  Management: Avoid concomitant use of palovarotene and moderate CYP3A4 inhibitors when possible. If combined, decrease palovarotene dose by 50% as described in the full interaction monograph. Monitor for palovarotene toxicities when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Panobinostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Panobinostat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PAZOPanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pemigatinib.  Management: If combined use cannot be avoided, reduce the pemigatinib dose from 13.5 mg daily to 9 mg daily, or from 9 mg daily to 4.5 mg daily. Resume prior pemigatinib dose after stopping the moderate inhibitor once 3 half-lives of the inhibitor has passed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pexidartinib.  Management: If combined use cannot be avoided, pexidartinib dose should be reduced. For the 125 mg capsules: reduce pexidartinib doses of 500 mg or 375 mg daily to 125 mg twice daily. Reduce pexidartinib 250 mg daily to 125 mg once daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimavanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Piperaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pirtobrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, decrease pralsetinib dose from 400 mg daily to 300 mg daily; from 300 mg daily to 200 mg daily; and from 200 mg daily to 100 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramipexole: DilTIAZem may enhance the hypotensive effect of Pramipexole. DilTIAZem may increase the serum concentration of Pramipexole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazepam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Prazepam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Praziquantel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QUEtiapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Quinidine (Non-Therapeutic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors. Monitor for increased ranolazine effects and toxicities during concomitant use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Red Yeast Rice: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin (and possibly other related compounds) may be increased.  Management: Initiate immediate release lovastatin at a dose of 10 mg/day, and do not exceed 20 mg/day for immediate or extended release lovastatin. Monitor closely for signs of lovastatin toxicity (eg, myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ribociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rifabutin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rimegepant.  Management: If taking rimegepant for the acute treatment of migraine, avoid a second dose of rimegepant within 48 hours when used concomitantly with moderate CYP3A4 inhibitors. No dose adjustment needed if using rimegepant for prevention of episodic migraine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rivaroxaban. This warning is more specifically for drugs that are inhibitors of both CYP3A4 and P-glycoprotein.  For erythromycin, refer to more specific erythromycin-rivaroxaban monograph recommendations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast-Containing Products: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Roflumilast-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rupatadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Rupatadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ruxolitinib (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ruxolitinib (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SAXagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selpercatinib.  Management: Avoid combination if possible. If use is necessary, reduce selpercatinib dose as follows: from 120 mg twice/day to 80 mg twice/day, or from 160 mg twice/day to 120 mg twice/day.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Selumetinib.  Management: Avoid concomitant use when possible. If combined, selumetinib dose reductions are recommended and vary based on body surface area and selumetinib dose. For details, see the full drug interaction monograph or selumetinib prescribing information.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sertindole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Silodosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: May decrease the serum concentration of DilTIAZem. DilTIAZem may increase the serum concentration of Simvastatin. Management: Avoid concurrent use of diltiazem with simvastatin when possible. If used together, limit adult doses to simvastatin 10 mg daily and diltiazem 240 mg per day; monitor closely for signs of simvastatin toxicity (eg, myositis, rhabdomyolysis).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sirolimus (Conventional).  Management: Monitor for increased serum concentrations of sirolimus if combined with a moderate CYP3A4 inhibitor. Lower initial sirolimus doses or sirolimus dose reductions will likely be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sirolimus (Protein Bound).  Management: Reduce the dose of protein bound sirolimus to 56 mg/m<sup>2</sup> when used concomitantly with a moderate CYP3A4 inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Solifenacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sonidegib.  Management: Avoid concomitant use of sonidegib and moderate CYP3A4 inhibitors when possible.  When concomitant use cannot be avoided, limit CYP3A4 inhibitor use to less than 14 days and monitor for sonidegib toxicity (particularly musculoskeletal adverse reactions).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Sparsentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of SUNItinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Suvorexant.  Management: The recommended dose of suvorexant is 5 mg daily in patients receiving a moderate CYP3A4 inhibitor. The dose can be increased to 10 mg daily (maximum dose) if necessary for efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Topical): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tacrolimus (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Talazoparib: DilTIAZem may increase the serum concentration of Talazoparib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tazemetostat.  Management: Avoid when possible. If combined, reduce tazemetostat dose from 800 mg twice daily to 400 mg twice daily, from 600 mg twice daily to 400 mg in AM and 200 mg in PM, or from 400 mg twice daily to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, concentrations of sirolimus may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terfenadine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Terfenadine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tezacaftor and Ivacaftor.  Management: If combined with moderate CYP3A4 inhibitors, give tezacaftor/ivacaftor in the morning, every other day; give ivacaftor in the morning, every other day on alternate days. Tezacaftor/ivacaftor dose depends on age and weight; see full Lexi-Interact monograph<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine.  Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tofacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolterodine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.  Management: Avoid this combination with Samsca brand of tolvaptan. Reduce dose for Jynarque brand: 90 mg AM and 30 mg PM, reduce to 45 mg AM and 15 mg PM; 60 mg AM and 30 mg PM, reduce to 30 mg AM and 15 mg PM; 45 mg AM and 15 mg PM, reduce to 15 mg AM and PM.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of TraMADol. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Triazolam.  Management: Consider triazolam dose reduction in patients receiving concomitant moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 50 mg and avoid a second dose for 24 hours when used with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Udenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ulipristal. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vamorolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vamorolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vardenafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vardenafil.  Management: Limit Levitra (vardenafil) dose to a single 5 mg dose within a 24-hour period if combined with moderate CYP3A4 inhibitors. Avoid concomitant use of Staxyn (vardenafil) and moderate CYP3A4 inhibitors. Combined use is contraindicated outside of the US.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vemurafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring concomitant treatment with moderate CYP3A4 inhibitors. Resume the previous venetoclax dose 2 to 3 days after discontinuation of moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Verapamil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinBLAStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinBLAStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinCRIStine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">VinCRIStine (Liposomal): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vindesine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vindesine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vinflunine: CYP3A4 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Vinflunine. CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vinflunine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Voclosporin.  Management: Decrease the voclosporin dose to 15.8 mg in the morning and 7.9 mg in the evening when combined with moderate CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vorapaxar. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zanubrutinib.  Management: Decrease the zanubrutinib dose to 80 mg twice daily during coadministration with a moderate CYP3A4 inhibitor. Further dose adjustments may be required for zanubrutinib toxicities, refer to prescribing information for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuranolone. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F160653"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Grapefruit juice may increase the serum concentration of diltiazem. Management: Monitor response to diltiazem with concurrent use.</p></div>
<div class="block rep_considerations drugH1Div" id="F58482045"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Diltiazem is not considered a preferred agent for use in pregnant patients; consider transitioning to a preferred agent in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p></div>
<div class="block pri drugH1Div" id="F160639"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events have been observed in animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of chronic hypertension during pregnancy is indicated, agents other than diltiazem may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]).</p></div>
<div class="block brc drugH1Div" id="F160640"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Diltiazem is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of diltiazem in breast milk are available from a case report. Oral diltiazem 60 mg four times a day was started in a mother on postpartum day 14 for arrythmia. Four days later maternal blood and breast milk were sampled. Peak breast milk concentrations of diltiazem were 200 ng/mL, similar to those in the maternal serum. Breast milk concentrations decreased to &lt;50 mg/mL 22 hours after the final diltiazem dose (Okada 1985).</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, considering the importance of treatment to the mother; however, other sources consider diltiazem compatible for use in patients who are breastfeeding (ESC [Cífková 2020]).</p></div>
<div class="block mop drugH1Div" id="F160626"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP; heart rate; liver function.</p></div>
<div class="block pha drugH1Div" id="F160616"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits calcium ion from entering the “slow channels” or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization; produces  relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina.</p></div>
<div class="block phk drugH1Div" id="F160635"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Oral: Immediate release tablet: 30 to 60 minutes; IV: Bolus: 3 minutes</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: IV: Bolus: 1 to 3 hours; Continuous infusion (after discontinuation): 0.5 to 10 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Immediate release tablet: ~98%; Extended release capsule: ~93% to &gt;95%</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 3 to 13 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 70% to 80%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic (extensive first-pass effect) via CYP-450 and conjugation; forms metabolites N-monodesmethyldiltiazem, desacetyldiltiazem, desacetyl-Nmonodesmethyldiltiazem, desacetyl-O-desmethyldiltiazem, and desacetyl-N, O-desmethyldiltiazem; following single IV injection, plasma concentrations of N-monodesmethyldiltiazem and desacetyldiltiazem are typically undetectable; however, these metabolites accumulate to detectable concentrations following 24-hour constant rate infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: ~40% (undergoes extensive first-pass metabolism)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Immediate release tablet: 3 to 4.5 hours; Extended release tablet: 6 to 9 hours; Extended release capsules: 4 to 9.5 hours; IV: single dose: ~3.4 hours; continuous infusion: 4 to 5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Immediate release tablet: 2 to 4 hours; Extended release tablet: 11 to 18 hours; Extended release capsule: 10 to 14 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (2% to 4% as unchanged drug); feces</p></div>
<div class="block phksp drugH1Div" id="F51153951"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Bioavailability is increased, and half-life is prolonged.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F160641"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Adizem XL | Cardil | Dilzem | Mono-tildiem | Tildiem</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Acalix | Acalix a.p. | Acalix cd | Acalix cronos | Dilauran | Diltenk | Diltenk ap 90 | Diltiazem fada | Diltiazem northia | Dilzen g | Hart | Hart a.p. | Hart cd | Incoril | Kaltiazem | Tilazem</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Corazem | Diltiastad | Diltiazem | Diltiazem genericon pharma | Dilzem | Dilzem rr</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo Diltiazem | Auscard | Cardizem | Cm diltiazem | Coras | Dbl diltiazem | Diltahexal | Diltiazem | Diltiazem actavis | Diltiazem an | Diltiazem bc | Diltiazem pfizer | Diltiazem sandoz | Dilzem | Dilzem cd | Sbpa diltiazem | Tw diltiazem | Vasocardol</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Adil | Cardil | Cardizem | Delcard | Diazem | Dilazem | Dilcontin | Dilgem | Dilti | Diltizem | Evascon | Herbesser | Litizem | Neocard</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Diltiazem eg | Diltiazem ratiopharm | Diltiazem sandoz | Diltiazem teva | Diltiazem teva generics belgium | Progor | Tildiem</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Aldizem | Altiazem rr | Diacordin | Diltiazem | Diltizem | Dilzem</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Angiolong | Angiolong ap | Balcor | Balcor e.v. | Calzem | Cardizem | Cloridrato de diltiazem | Cordil | Diltiacor | Diltipress | Diltizem | Diltor cd | Incoril</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Diltiazem mepha | Diltiazem skyepharma | Dilzem</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Acasmul | Cordis | Grifodilzem | Incoril | Tilazem | Tildiem</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai ke lang | Di heng | Diltiazem | Dilzem sr | Ergolan | Herbesser | Jian er xin | Mono-tildiem | Qin er kang | Tian er xin | Xintai</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Angiotrofin | Angoral | Corazem cd | Diltiasyn | Diltiazem | Tilazem</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Blocalcin | Diacordin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Corazet Diltiazem | Dil sanorania | Dilsal | Dilta | Diltabeta | Diltahexal | Diltapham | Diltaretard | Dilti | Diltia | Diltiagamma | Diltiamerck | Diltiazem | Diltiazem 1 A Pharm | Diltiazem ethypharm | Diltiazem Siga | Diltiazem stada | Diltiazem Temmler | Diltiazem Verla | Diltiuc | Dilzanton | Dilzem | Dilzicardin | Tilker</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Myonil</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Altiazem | Angiotrofin | Cirilen | Cirilen CD | Diltiax | Diltiazem | Incoril | Lacerol | Lacerol HTA | Lufrazem | Rozen | Tilazem</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Arterodoxial | Cirilen | Diltiazem | Incoril | Incoril ap | Incoril monodosis | Tilazem</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Altiazem rr | Cardil | Dilatam | Dilrene | Diltiazem | Diltisan | Dilzem</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Altiazem | Angitect | Delay Tiazem | Diltacor XL | Diltiazem | Mono-tildiem | Peltiam | Telzim | Tildiem</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Angiodrox | Cardiser | Carreldon | Corolater | Cronodine | Dilaclan | Dilaclan hta | Diltiazem alter | Diltiazem bayvit | Diltiazem cinfa | Diltiazem edigen | Diltiazem esteve | Diltiazem mundogen | Diltiazem qualix | Diltiazem Ranbaxy | Diltiazem stada | Diltiwas | Diltiwas retard | Dinisor | Doclis | Lacerol | Lacerol cor | Masdil | Tilker | Trumsal | Uni masdil</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cardizem | Dilmin | Dilpral | Diltical | Dilzem | Viazem</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Bi tildiem | Deltazen | Diacor | Dilrene | Diltiazem | Diltiazem arrow | Diltiazem bgr | Diltiazem biogaran | Diltiazem cristers | Diltiazem g gam | Diltiazem gnr | Diltiazem ivax | Diltiazem merck | Diltiazem msd | Diltiazem Panpharma | Diltiazem ratiopharm | Diltiazem rpg | Diltiazem sandoz | Diltiazem teva | Diltiazem teva sante | Diltiazem Zentiva | Diltiazem zentiva lab | Mono tildiem | Monotildiem | Tildiem</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Adizem | Angiozem | Angitil | Bi carzem | Britiazim | Calazem | Calcicard | Calcicard 3m | Dilcardia | Diltiazem | Diltiazem arrow | Diltiazem berk | Diltiazem kent | Diltiazem sandoz | Diltiazem teva | Dilzem | Disogram | Horizem | Kenzem | Metazem | Optil | Retalzem | Slozem | Tiamex | Tildiem | Tildiem la | Viazem | Zemret | Zemtard | Zildil</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Alfener | Cardil | Corsenile | Diltelan | Dilzanol | Dipen | Elvesil | Ergoclavin | Mavitalon | Mycarzem | Natasadol | Rubiten | Saubasin | Ternel | Tildiem | Zilden</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo diltiaz | Diazem | Dilatam | Dilem | Diltan | Diltiazem | Herbesser | Syn-diltiazem | Tildiem | Wontizem</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Aldizem | Diltiazem Pliva</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Blocalcin | Dilrene | Diltan-sr | Diltiazem b | Dilzem</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Carditen | Cardyne | Cordila | Cordizem | Dilbres | Dilmen | Dilso | Diltan | Diltiazem | Diltikor | Farmabes | Herbesser | Herbesser CD | Lanodil</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Adizem | Diltam | Diltiazem | Dilzem | Dilzem sr | Entrydil | Tildiem | Zemtard</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Adizem CD | Dilatam | Levodex | Levozem</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Altiazem | Angizem | Cardem | Channel | Coriem-xl | Delwin | Dicard | Dilcal | Dilcardia | Dilcare | Dilcontin | Dilgard | Dilmax | Dilocor | Dilt | Diltanol | Diltara | Dilter | Dilti | Diltiaz | Diltilong | Diltime | Dilzem | Dilzem sr | Dilzor | Dtm | Dz | Dzm | Heartil | Icidil | Ionozem | Ionozem cd | Isdil | Iski | Kaizem | Lodil | Masdil | Onzem | Q-dil-cd | Sirdil | Tiacard</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">AwaDilazim</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Korzem | Korzem R</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Altiazem | Angipress | Angizem | Carzem | Citizem | Diacardin | Diladel | Dilem | Diliter | Diltiazem | Diltiazem doc | Diltiazem drm | Diltiazem eg | Diltiazem Mylan | Diltiazem San | Diltiazem sandoz | Dilzene | Dilzener | Etyzem | Longazem | Tildiem</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Altiazem | Bi tildiem | Corzem | Dilzacard | Dilzem | Mono tildiem | Tildiem</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Calnurs | Clarute santen | Clarute sawai | Clarute yoshitomi | Coroherser nichiiko | Coroherser r | Diltiazem hcl isei | Diltiazem hcl ohara | Frotty | Gadoserin | Helsibon | Hemarekeat | Herbesser | Herbesser r | Herbesser r100 | Herbesser r200 | Hirosutas r | Lutianon r | Marumunen | Miocardie nissin | Nackless | Paretnamin | Paretnamin taisho | Pazeadin | Seresnatt | Sunlight | Tiaves hexal | Tiaves nichiiko | Yohtiazem | Yohtiazem mita | Yohtiazem nichiiko | Yohtiazem yoshindo | Youtiazem | Ziruvate choseido | Ziruvate kayaku | Ziruvate nisshin kyorin sei</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Dilcontin xl | Mono tildiem sr</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cardiazem | Cardiben | Carzem | Deltazem | Diltam | Diltelan | Diltiazem | Diltren | Heartzem | Herben | Herben sr | Heripesa | Miozem | Tazem | Tiaben</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Bi tildiem | Diltan | Dilzem | Mono-tildiem | Tildiem</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Adizem XL | Altiazem | Apo diltiaz | Apo Diltiazem | Diltan | Diltiaretard | Diltiaz | Diltiazem | Dilzem | Tildiem | Zaldem</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Altiazem rr | Apo Diltiazem | Blocalcin | Cardil | Diacordin | Diazem | Dilrene | Diltiazem | Diltisan | Diltizem | Dilzem</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Diltahexal | Diltiazem eg | Diltiazem sandoz | Progor | Tildiem</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Aldizem | Altiazem rr | Blocalcin | Cardil | Diacordin | Dilatan | Dilrene | Dilteks | Diltiazem | Diltiazem ratiopharm | Diltisan | Diltizem | Dilzem</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Adizem | Altiazem | Bi tildiem | Cronodine | Dilrene | Mono tildiem | Progor | Retalzem | Tildiem</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Angiotrofin | Angiotrofin a.p. | Angiotrofin retard | Anremed | Dasav | Diltiazem g.i. | Sertidel | Tilazem</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Apo Diltiazem | Calcizem | Cardil | Cascor XL | Diazem | Dilcard | Dilem | Diltizem | Herbesser | Mono-tildiem | Tildiem</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Diloc | Diltiazem HCL | Diltiazem hcl a | Diltiazem hcl cr | Diltiazem hcl flx | Diltiazem HCl sandoz | Diltiazem hcl teva | Surazem | Tiadil | Tildiem | Tildiem lp | Viazem</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Cardizem | Cardizem Retard | Diltiazem | Diltiazem ratiopharm | Diltikard | Kardil | Tildiem | Tildiem la | Tilker</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo Diltiazem | Cardizem | Cardizem cd | Dilacor XR | Dilcard | Diltiazem cd | Diltiazem HCL | Dilzem</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Diltiazem | Diltiazen clorhidrato | Dodexen | Dodexen ap | Grifodilzem | Incoril | Tilazem</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Angiozem | Cordazem | Dilatam | Dilcardia | Diltac | Diltelan | Diltiazem | Diltiazem Pacific | Dilzem | Dyalac | Forzem | Novoptin | Sandizem | Servazen | Tildiem | Vasmulax | Zandil | Zemdil</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Angizem | Calcard | Calcicor | Calzem | Cardiazem | Dazil | Deltazem | Desbon | Diacord | Diltiazaf | Dilzem | Dtz | Etizem | Herbesser | Lacerol | Locard | Metazem | Perlita sr | Procard | Quzem | Tiazem | Zem | Zemycard</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aldizem | Apo diltiaz | Blocalcin | Diacordin | Dilocard | Dilrene lp | Diltiazem | Diltiazem HCL | Dilzem | Entrydil | Oxycardil | Poltiazem | Tildiem | Zilden</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cardizem | Cardizem cd | Cardizem la | Cartia xt | Dilacor XR | Dilt-xr | Diltia | Diltiazem | Diltiazem 12hr | Diltiazem cd | Diltiazem HCL | Diltiazem Hcl cd | Diltiazem HCL extended release | Diltiazem hydrochloride extended release | Diltiazem xr | Diltzac | Taztia xt | Tiadylt er | Tiazac</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Alandiem | Altiazem | Balcor | Cal-antagon | Dilfar | Dilongo | Diltiangina | Diltiazem | Diltiazem sandoz | Diltiem | Duplide | Etizem | Herbesser | Pentilzeno | Tiadil</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Acalix | Acalix cd | Angiten | Cardizen | Diltiazem prosalud | Hart | Hart a.p. | Incoril | Incoril ap | Incoril monodosis | Nortenol</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Apo-Diltiaz | Bi-Tildiem | Dilzem | Dilzem Retard | Mono-Tildiem | Riazem | Tildiem</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Aldizem | Altiazem rr | Asdilt | Blocalcin | Cardil | Diacordin | Dilatam | Diltiazem | Diltiazem arena | Diltiazem bioeel | Diltiazem eipico | Diltiazem lph | Diltiazem sr rompharm | Diltisan | Diltizem | Dilzem</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aldizem | Altiazem rr | Angizem | Cardil | Diacordin | Diazem | Dilrene | Diltiazem | Diltiazem Lannacher | Diltiazem ratiopharm | Diltizem | Dilzem</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo diltaz | Bi tildiem | Dilzem | Monotildiem | Riazem | Tildiem</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cardizem | Cardizem Retard | Coramil | Diltelan | Diltikard</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Angizem | Beatizem | Cardil | Cardium | Herbesser | Mono-tildiem</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Aldizem | Diltiazem | Dilzem</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Altiazem rr | Blocalcin | Diacordin | Dilrene lp | Dilzem</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Altiazem | Angizem | Apo diltiaz | Cardiazem | Cardil | Carzem | Cascor | Denazox | Dilatam | Dilcardia | Dilem | Dilizem | Diltiazem | Ditizem | Herbesser | Herbesser 90 | Herbesser r | Herbie | Medozem | Progor | Seresnatt | Tildiem</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Altiazem | Bi tildiem | Cardiadil | Dilrene | Dipen | Mono tiazem lp | Mono-tildiem | Tildiem | Zilden</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Altizem | Dilticard | Diltizem | Progor | Tiacard</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Aerisin | Altiazem | Angeltension | Calnurs | Cardil | Cardizem | Cartil | Coroherser | Dilazem | Dilem | Diltahexal | Diltelan | Diltiazem | Diltisser | Dilzem | Diyazen | Etizem | Hagen | Herbesser | Herzen | Hesor | Latiazem | Miocardie | Miocaride | Nakasser | Pertiazem | Progor | Seresnatt | Silzem | Suboshin | Tazem | Tiaves | Yohtiazem</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Aldizem | Angizem | Cardil | Diacardil | Diacordin retard | Dilrene | Diltiazem | Diltiazem alkaloid | Diltisan | Retalzem</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Dilcontin</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cirilen | Cirilen CD | Dilangin | Diltiasur | Diltiazem | Dilzem | Grifodilzem | Incoril | Kardiozem | Tilazem</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acalix | Corazem | Cordisil | Daltazen | Diltiazem | Distiazem | Presoquin | Tilazem</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Bidizem | Bidizem mr | Tilhasan | Tilhazem</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Diatil | Dilatam | Rolab-diltiazem | Tilazem | Zildem</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AA-Diltiaz.1">
<a name="AA-Diltiaz.1"></a>AA-Diltiaz (diltiazem) [product monograph]. Vaughan, Ontario, Canada: AA Pharma Inc; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8249821">
<a name="8249821"></a>Ahmad S. Diltiazem myopathy. <i>Am Heart J</i>. 1993;126(6):1494‐1495. doi:10.1016/0002-8703(93)90572-q<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/8249821/pubmed" id="8249821" target="_blank">8249821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29084731">
<a name="29084731"></a>Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in <i>Circulation</i>. 2018;138(13):e419-e420]. <i>Circulation</i>. 2018;138(13):e272-e391. doi: 10.1161/CIR.0000000000000549.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/29084731/pubmed" id="29084731" target="_blank">29084731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8879325">
<a name="8879325"></a>Allen LV Jr, Erickson MA 3rd. Stability of baclofen, captopril, diltiazem hydrochloride, dipyridamole, and flecainide acetate in extemporaneously compounded oral liquids. <i>Am J Health Syst Pharm</i>. 1996;53(18):2179-2184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/8879325/pubmed" id="8879325" target="_blank">8879325</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8013508">
<a name="8013508"></a>Andrivet P, Beaslay V, Kiger JP, vu Gnoc C. Complete sinus arrest during diltiazem therapy; clinical correlates and efficacy of intravenous calcium. <i>Eur Heart J</i>. 1994;15(3):350‐354. doi:10.1093/oxfordjournals.eurheartj.a060502<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/8013508/pubmed" id="8013508" target="_blank">8013508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ApoDiltiaz.2018.09">
<a name="ApoDiltiaz.2018.09"></a>Apo-Diltiaz (diltiazem) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; September 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21518977">
<a name="21518977"></a>Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents [published corrections appear in <i>Circulation</i>. 2011;123(21):e616; <i>Circulation</i>. 2011;124(5):e175; <i>Circulation</i> 2016;133(24):e715]. <i>Circulation.</i> 2011;123(21):2434-2506.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/21518977/pubmed" id="21518977" target="_blank">21518977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17565025">
<a name="17565025"></a>Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: Updated ACCP evidence-based clinical practice guidelines. <i>Chest.</i> 2007;131(6):1917-1928.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/17565025/pubmed" id="17565025" target="_blank">17565025</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31020549">
<a name="31020549"></a>Bellón T. Mechanisms of severe cutaneous adverse reactions: Recent advances. <i>Drug Saf</i>. 2019;42(8):973‐992. doi:10.1007/s40264-019-00825-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/31020549/pubmed" id="31020549" target="_blank">31020549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pinto.2019">
<a name="Pinto.2019"></a>Beltrame JF, Crea F. Vasospastic angina. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 11, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3281058">
<a name="3281058"></a>Bertorini TE, Palmieri GMA, Griffin JW, et al. Effect of chronic treatment with the calcium antagonist diltiazem in Duchenne muscular dystrophy. <i>Neurology.</i> 1988;38(4):609-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/3281058/pubmed" id="3281058" target="_blank">3281058</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3422722">
<a name="3422722"></a>Bowman JM, Levy BA, Grubb RV. Gingival overgrowth induced by diltiazem. A case report. <i>Oral Surg Oral Med Oral Pathol</i>. 1988;65(2):183‐185. doi:10.1016/0030-4220(88)90163-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/3422722/pubmed" id="3422722" target="_blank">3422722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23847692">
<a name="23847692"></a>Brenes JA, Cha YM. Diltiazem-induced transient complete atrioventricular block in an elderly patient with acute on chronic renal failure. <i>Open Cardiovasc Med J</i>. 2013;7:23‐26. doi:10.2174/1874192401307010023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/23847692/pubmed" id="23847692" target="_blank">23847692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30028512">
<a name="30028512"></a>Brockow K, Ardern-Jones MR, Mockenhaupt M, et al. EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. <i>Allergy</i>. 2019;74(1):14‐27. doi:10.1111/all.13562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/30028512/pubmed" id="30028512" target="_blank">30028512</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23846341">
<a name="23846341"></a>Campbell M, Ahluwalia J, Watson AC. Diltiazem-associated hyperpigmentation. <i>J Gen Intern Med</i>. 2013;28(12):1676. doi:10.1007/s11606-013-2530-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/23846341/pubmed" id="23846341" target="_blank">23846341</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cardizem.2016.11">
<a name="Cardizem.2016.11"></a>Cardizem (diltiazem hydrochloride) tablets [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cardizem.2017.01">
<a name="Cardizem.2017.01"></a>Cardizem (diltiazem hydrochloride) capsules [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; January 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cardizem.2014.11">
<a name="Cardizem.2014.11"></a>Cardizem (diltiazem hydrochloride) direct compression tablets [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; November 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CardizemCD.2017.01">
<a name="CardizemCD.2017.01"></a>Cardizem CD (diltiazem hydrochloride) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CardizemCD.2019.06">
<a name="CardizemCD.2019.06"></a>Cardizem CD (diltiazem hydrochloride) [product monograph]. Laval, Quebec, Canada: Bausch Health Canada Inc; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CardizemLA.2019.09">
<a name="CardizemLA.2019.09"></a>Cardizem LA (diltiazem hydrochloride) [prescribing information]. Bridgewater, NJ: Bausch Health US LLC; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CartiaXT.2017.11">
<a name="CartiaXT.2017.11"></a>Cartia XT (diltiazem hydrochloride) [prescribing information]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc; August 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12748199">
<a name="12748199"></a>Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. <i>JAMA.</i> 2003;289(19):2560-2572.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/12748199/pubmed" id="12748199" target="_blank">12748199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14616146">
<a name="14616146"></a>Cholez C, Trechot P, Schmutz JL, Faure G, Bene MC, Barbaud A. Maculopapular rash induced by diltiazem: allergological investigations in four patients and cross reactions between calcium channel blockers. <i>Allergy</i>. 2003;58(11):1207‐1209. doi:10.1034/j.1398-9995.2003.00222.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/14616146/pubmed" id="14616146" target="_blank">14616146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7477141">
<a name="7477141"></a>Crowson AN, Magro CM. Diltiazem and subacute cutaneous lupus erythematosus-like lesions. <i>N Engl J Med</i>. 1995;333(21):1429.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/7477141/pubmed" id="7477141" target="_blank">7477141</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24042208">
<a name="24042208"></a>Deng W, Farricielli L. Hypoxic hepatitis and acute liver failure in a patient with newly onset atrial fibrillation and diltiazem infusion. <i>BMJ Case Rep</i>. 2013;2013:bcr2013200573. doi:10.1136/bcr-2013-200573<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/24042208/pubmed" id="24042208" target="_blank">24042208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DiltXR.2012.07">
<a name="DiltXR.2012.07"></a>Dilt-XR (diltiazem) [prescribing information]. Weston, FL: Apotex; July 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glenmark.1">
<a name="Glenmark.1"></a>Diltiazem extended-release capsules, USP [prescribing information]. Memphis, TN: Northstar Rx LLC; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DiltiazemInjection.2014.06">
<a name="DiltiazemInjection.2014.06"></a>Diltiazem injection [prescribing information]. E Windsor, NJ: Eugia US LLC; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DiltiazemInjection.2010.11">
<a name="DiltiazemInjection.2010.11"></a>Diltiazem injection [product monograph]. Montreal, Quebec, Canada: Omega Laboratories Limited; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3542336">
<a name="3542336"></a>Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. <i>Clin Pharmacokinet</i>. 1986;11(6):425-449. doi:10.2165/00003088-198611060-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/3542336/pubmed" id="3542336" target="_blank">3542336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10774785">
<a name="10774785"></a>Edoute Y, Nagachandran P, Svirski B, Ben-Ami H. Cardiovascular adverse drug reaction associated with combined beta-adrenergic and calcium entry-blocking agents. <i>J Cardiovasc Pharmacol</i>. 2000;35(4):556‐559. doi:10.1097/00005344-200004000-00007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/10774785/pubmed" id="10774785" target="_blank">10774785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1894861">
<a name="1894861"></a>Ellenbogen KA, Dias VC, Plumb VJ, Heywood JT, Mirvis DM. A placebo-controlled trial of continuous intravenous diltiazem infusion for 24-hour heart rate control during atrial fibrillation and atrial flutter: a multicenter study. <i>J Am Coll Cardiol</i>. 1991;18(4):891-897. doi:10.1016/0735-1097(91)90743-s<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/1894861/pubmed" id="1894861" target="_blank">1894861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956217">
<a name="20956217"></a>Field JM, Hazinski MF, Sayre MR, et al. Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation. </i>2010;122(18)(suppl 3):640-656.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/20956217/pubmed" id="20956217" target="_blank">20956217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al; American College of Cardiology Foundation/American Heart Association Task Force. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons [published correction appears in <i>Circulation</i>. 2014;129(16):e463]. <i>Circulation.</i> 2012;126(25):e354-e471.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11149130">
<a name="11149130"></a>Flynn JT, Pasko DA. Calcium channel blockers: Pharmacology and place in therapy of pediatric hypertension. <i>Pediatr Nephrol.</i> 2000;15(3-4):302-316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/11149130/pubmed" id="11149130" target="_blank">11149130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8352682">
<a name="8352682"></a>Friedland S, Kaplan S, Lahav M, Shapiro A. Proptosis and periorbital edema due to diltiazem treatment. <i>Arch Ophthalmol</i>. 1993;111(8):1027‐1028. doi:10.1001/archopht.1993.01090080023010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/8352682/pubmed" id="8352682" target="_blank">8352682</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16904574">
<a name="16904574"></a>Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. <i>J Am Coll Cardiol.</i> 2006;48(4):854-906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/16904574/pubmed" id="16904574" target="_blank">16904574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16778429">
<a name="16778429"></a>Gesierich A, Rose C, Brocker EB, Trautmann A, Leverkus M. Acute generalised exanthematous pustulosis with subepidermal blisters of the distal extremities induced by diltiazem. <i>Dermatology</i>. 2006;213(1):48‐49. doi:10.1159/000092840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/16778429/pubmed" id="16778429" target="_blank">16778429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12570960">
<a name="12570960"></a>Gibbons RJ, Abrams J, Chatterjee K, et al; American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina—summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). <i>J Am Coll Cardiol</i>. 2003;41(1):159-168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/12570960/pubmed" id="12570960" target="_blank">12570960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3526151">
<a name="3526151"></a>Gibson RS, Boden WE, Theroux P, et al. Diltiazem and reinfarction with non-Q-wave myocardial infarction. <i>N Engl J Med.</i> 1986;315(7):423-429.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/3526151/pubmed" id="3526151" target="_blank">3526151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1279611">
<a name="1279611"></a>Gill JS, Ward DE, Camm JA. Comparison of verapamil and diltiazem in the suppression of idiopathic ventricular tachycardia. <i>Pacing Clin Electrophysiol.</i> 1992;15(11, pt 2):2122-2126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/1279611/pubmed" id="1279611" target="_blank">1279611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published correction appears in Hypertension. 2014 Jun;63(6):e175]. <i>Hypertension</i>. 2014;63(4):878‐885. doi:10.1161/HYP.0000000000000003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16045866">
<a name="16045866"></a>Gonzalo Garijo MA, Pérez Calderón R, de Argila Fernández-Durán D, Rangel Mayoral JF. Cutaneous reactions due to diltiazem and cross reactivity with other calcium channel blockers. <i>Allergol Immunopathol (Madr)</i>. 2005;33(4):238‐240. doi:10.1157/13077752<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/16045866/pubmed" id="16045866" target="_blank">16045866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3392246">
<a name="3392246"></a>Grech-Bélanger O, Langlois S, LeBoeuf E. Pharmacokinetics of diltiazem in patients undergoing continuous ambulatory peritoneal dialysis. <i>J Clin Pharmacol</i>. 1988;28(5):477-480. doi:10.1002/j.1552-4604.1988.tb05763.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/3392246/pubmed" id="3392246" target="_blank">3392246</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7110278">
<a name="7110278"></a>Hossack KF. Conduction abnormalities due to diltiazem. <i>N Engl J Med</i>. 1982;307(15):953‐954. doi:10.1056/nejm198210073071516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/7110278/pubmed" id="7110278" target="_blank">7110278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017548">
<a name="36017548"></a>Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. <i>Eur Heart J.</i> 2022;43(38):3618-3731. doi:10.1093/eurheartj/ehac237<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/36017548/pubmed" id="36017548" target="_blank">36017548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3943233">
<a name="3943233"></a>Imamura T, Koiwaya Y, Nakamura M. Sinoatrial block induced by oral diltiazem. <i>Clin Cardiol</i>. 1986;9(1):33‐34. doi:10.1002/clc.4960090108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/3943233/pubmed" id="3943233" target="_blank">3943233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11320702">
<a name="11320702"></a>Inui S, Itami S, Yoshikawa K. A case of lichenoid purpura possibly caused by diltiazem hydrochloride. <i>J Dermatol</i>. 2001;28(2):100‐102. doi:10.1111/j.1346-8138.2001.tb00098.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/11320702/pubmed" id="11320702" target="_blank">11320702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6621654">
<a name="6621654"></a>Ishikawa T, Imamura T, Koiwaya Y, Tanaka K. Atrioventricular dissociation and sinus arrest induced by oral diltiazem. <i>N Engl J Med</i>. 1983;309(18):1124‐1125. doi:10.1056/NEJM198311033091813<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/6621654/pubmed" id="6621654" target="_blank">6621654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24685669">
<a name="24685669"></a>January CT, Wann LS, Alpert JS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol</i>. 2014;64(21):e1-e76. doi: 10.1016/j.jacc.2014.03.022.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/24685669/pubmed" id="24685669" target="_blank">24685669</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30703530">
<a name="30703530"></a>January CT, Wann LS, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>. 2019;16(8):e66‐e93. doi:10.1016/j.hrthm.2019.01.024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/30703530/pubmed" id="30703530" target="_blank">30703530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kannam.2019">
<a name="Kannam.2019"></a>Kannam JP, Aroesty JM, Gersh BJ. Calcium channel blockers in the management of stable angina pectoris. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 11, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ganz.2019">
<a name="Ganz.2019"></a>Kaplan R. Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8340532">
<a name="8340532"></a>Kitamura K, Kanasashi M, Suga C, Saito S, Yoshida S, Ikezawa Z. Cutaneous reactions induced by calcium channel blocker: high frequency of psoriasiform eruptions. <i>J Dermatol</i>. 1993;20(5):279‐286. doi:10.1111/j.1346-8138.1993.tb01392.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/8340532/pubmed" id="8340532" target="_blank">8340532</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8879597">
<a name="8879597"></a>Kjeldsen SE, Syvertsen JO, Hedner T. Cardiac conduction with diltiazem and beta-blockade combined. A review and report on cases. <i>Blood Press</i>. 1996;5(5):260‐263. doi:10.3109/08037059609078057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/8879597/pubmed" id="8879597" target="_blank">8879597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956230">
<a name="20956230"></a>Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation.</i> 2010;122(18)(suppl 3):876-908.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/20956230/pubmed" id="20956230" target="_blank">20956230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30660783">
<a name="30660783"></a>Klinger JR, Elliott CG, Levine DJ, et al. Therapy for pulmonary arterial hypertension in adults: update of the CHEST guideline and expert panel report. <i>Chest</i>. 2019;155(3):565-586. doi: 10.1016/j.chest.2018.11.030.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/30660783/pubmed" id="30660783" target="_blank">30660783</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9486675">
<a name="9486675"></a>Knowles S, Gupta AK, Shear NH. The spectrum of cutaneous reactions associated with diltiazem: three cases and a review of the literature. <i>J Am Acad Dermatol</i>. 1998;38(2 Pt 1):201‐206. doi:10.1016/s0190-9622(98)70241-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/9486675/pubmed" id="9486675" target="_blank">9486675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23878619">
<a name="23878619"></a>Koskinas KC, Lillis L, Ziakas A. Diltiazem: a reversible cause of atrioventricular block - until proven otherwise. <i>Open Cardiovasc Med J</i>. 2013;7:46. doi:10.2174/1874192401307010046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/23878619/pubmed" id="23878619" target="_blank">23878619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20883365">
<a name="20883365"></a>Kubo Y, Fukumoto D, Ishigami T, Hida Y, Arase S. Diltiazem-associated photodistributed hyperpigmentation: report of two Japanese cases and published work review. <i>J Dermatol</i>. 2010;37(9):807‐811. doi:10.1111/j.1346-8138.2010.00858.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/20883365/pubmed" id="20883365" target="_blank">20883365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33391915">
<a name="33391915"></a>Lee WK, Shameem M, Ganti L, Banerjee PR, Shivdat J. Cardiac arrest following treatment with diltiazem for atrial fibrillation with rapid ventricular response. <i>Cureus</i>. 2020;12(11):e11678. doi:10.7759/cureus.11678<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/33391915/pubmed" id="33391915" target="_blank">33391915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management.<i> J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.2019">
<a name="Mann.2019"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manolis.2019">
<a name="Manolis.2019"></a>Manolis AS. Premature ventricular complexes: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 16, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14607462">
<a name="14607462"></a>Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the European Society of Cardiology Committee for Practice Guidelines. <i>J Am Coll Cardiol.</i> 2003;42(9):1687-1713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/14607462/pubmed" id="14607462" target="_blank">14607462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14607462">
<a name="14607462"></a>Matzim LA (diltiazem) [prescribing information]. Parsippany, NJ: Actavis Pharma, Inc; January 2024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/14607462/pubmed" id="14607462" target="_blank">14607462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19389575">
<a name="19389575"></a>McLaughlin VV, Archer SL, Badesch DB, et al; American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. <i>J Am Coll Cardiol</i>. 2009;53(17):1573-1619. doi: 10.1016/j.jacc.2009.01.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/19389575/pubmed" id="19389575" target="_blank">19389575</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9399624">
<a name="9399624"></a>Michalets EL, Jackson DV. Diltiazem-associated thrombocytopenia. <i>Pharmacotherapy</i>. 1997;17(6):1345‐1348.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/9399624/pubmed" id="9399624" target="_blank">9399624</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20543192">
<a name="20543192"></a>Montani D, Savale L, Natali D, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. <i>Eur Heart J</i>. 2010;31(15):1898-1907. doi: 10.1093/eurheartj/ehq170.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/20543192/pubmed" id="20543192" target="_blank">20543192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Moragan.2019">
<a name="Moragan.2019"></a>Morgan JP. Clinical manifestations, diagnosis, and management of the cardiovascular complications of cocaine abuse. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8820477">
<a name="8820477"></a>Moser LR, Panacek EA, Munger MA. Fatality due to intravenous diltiazem for acute ventricular rate control. <i>Pharmacotherapy</i>. 1996;16(2):306‐310.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/8820477/pubmed" id="8820477" target="_blank">8820477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [published correction appears in <i>Circulation</i>. 2011;123(6):e236. <i>Circulation</i>. 2013;128(25):e480]. <i>Circulation</i>. 2010;122(18)(suppl 3):S729-S767. doi: 10.1161/CIRCULATIONAHA.110.970988.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9022661">
<a name="9022661"></a>Odeh M. Exfoliative dermatitis associated with diltiazem. <i>J Toxicol Clin Toxicol</i>. 1997;35(1):101‐104. doi:10.3109/15563659709001174<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/9022661/pubmed" id="9022661" target="_blank">9022661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3974691">
<a name="3974691"></a>Okada M, Inoue H, Nakamura Y, et al. Excretion of Diltiazem in Human Milk. <i>N Engl J Med.</i> 1985;312(15):992-993.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/3974691/pubmed" id="3974691" target="_blank">3974691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33229116">
<a name="33229116"></a>Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/33229116/pubmed" id="33229116" target="_blank">33229116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530749">
<a name="22530749"></a>Osmonov D, Erdinler I, Ozcan KS, et al. Management of patients with drug-induced atrioventricular block. <i>Pacing Clin Electrophysiol</i>. 2012;35(7):804‐810. doi:10.1111/j.1540-8159.2012.03410.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/22530749/pubmed" id="22530749" target="_blank">22530749</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26399663">
<a name="26399663"></a>Page RL, Joglar JA, Caldwell MA, et al; Evidence Review Committee Chair. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in <i>Circulation</i>. 2016;134(11):e234-e235]. <i>Circulation</i>. 2016;133(14):e506-e574. doi: 10.1161/CIR.0000000000000311.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/26399663/pubmed" id="26399663" target="_blank">26399663</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Park.2014">
<a name="Park.2014"></a>Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11009280">
<a name="11009280"></a>Pass RH, Liberman L, Al-Fayaddh M, et al. Continuous Intravenous Diltiazem Infusion for Short-Term Ventricular Rate Control in Children. <i>Am J Cardiol.</i> 2000;86(5):559-62, A9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/11009280/pubmed" id="11009280" target="_blank">11009280</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37456398">
<a name="37456398"></a>Perozo MA, Escaño L, Thompson R, Cedeno H. A rare case of diltiazem-induced photosensitivity. <i>Cureus</i>. 2023;15(6):e40376. doi:10.7759/cureus.40376<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/37456398/pubmed" id="37456398" target="_blank">37456398</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6873142">
<a name="6873142"></a>Pozet N, Brazier JL, Aïssa AH, et al. Pharmacokinetics of diltiazem in severe renal failure. <i>Eur J Clin Pharmacol</i>. 1983;24(5):635-638. doi:10.1007/BF00542213<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/6873142/pubmed" id="6873142" target="_blank">6873142</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prutkin.2019">
<a name="Prutkin.2019"></a>Prutkin JM. Overview of the acute management of tachyarrhythmias. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2450898">
<a name="2450898"></a>Prystowsky EN. The effects of slow channel blockers and beta blockers on atrioventricular nodal conduction. <i>J Clin Pharmacol</i>. 1988;28(1):6‐21. doi:10.1002/j.1552-4604.1988.tb03095.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/2450898/pubmed" id="2450898" target="_blank">2450898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17244089">
<a name="17244089"></a>Ramírez A, Pérez-Pérez L, Fernández-Redondo V, Toribio J. Photoallergic dermatitis induced by diltiazem. <i>Contact Dermatitis</i>. 2007;56(2):118‐119. doi:10.1111/j.1600-0536.2007.00967.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/17244089/pubmed" id="17244089" target="_blank">17244089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27025295">
<a name="27025295"></a>Sáenz de Santa María García M, Noguerado-Mellado B, Rojas Pérez-Ezquerra P, Hernandez-Aragües I, De Barrio Fernández M. Acute generalized exanthematous pustulosis due to diltiazem: Investigation of cross-reactivity with other calcium channel blockers. <i>J Allergy Clin Immunol Pract</i>. 2016;4(4):765‐766. doi:10.1016/j.jaip.2016.02.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/27025295/pubmed" id="27025295" target="_blank">27025295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1674455">
<a name="1674455"></a>Sagie A, Strasberg B, Kusnieck J, Sclarovsky S. Symptomatic bradycardia induced by the combination of oral diltiazem and beta blockers. <i>Clin Cardiol</i>. 1991;14(4):314‐316. doi:10.1002/clc.4960140406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/1674455/pubmed" id="1674455" target="_blank">1674455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16490848">
<a name="16490848"></a>Saladi RN, Cohen SR, Phelps RG, Persaud AN, Rudikoff D. Diltiazem induces severe photodistributed hyperpigmentation: case series, histoimmunopathology, management, and review of the literature. <i>Arch Dermatol</i>. 2006;142(2):206‐210. doi:10.1001/archderm.142.2.206<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/16490848/pubmed" id="16490848" target="_blank">16490848</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8096307">
<a name="8096307"></a>Sanders CJ, Neumann HA. Erythema multiforme, Stevens-Johnson syndrome, and diltiazem. <i>Lancet</i>. 1993;341(8850):967. doi:10.1016/0140-6736(93)91264-m<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/8096307/pubmed" id="8096307" target="_blank">8096307</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3120959">
<a name="3120959"></a>Shallcross H, Padley SP, Glynn MJ, Gibbs DD. Fatal renal and hepatic toxicity after treatment with diltiazem. <i>Br Med J (Clin Res Ed)</i>. 1987;295(6608):1236‐1237. doi:10.1136/bmj.295.6608.1236<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/3120959/pubmed" id="3120959" target="_blank">3120959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3211830">
<a name="3211830"></a>Sheehan-Dare RA, Goodfield MJ. Widespread cutaneous vasculitis associated with diltiazem. <i>Postgrad Med J</i>. 1988;64(752):467‐468. doi:10.1136/pgmj.64.752.467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/3211830/pubmed" id="3211830" target="_blank">3211830</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12589171">
<a name="12589171"></a>Sica DA, Gehr TW. Calcium-channel blockers and end-stage renal disease: pharmacokinetic and pharmacodynamic considerations. <i>Curr Opin Nephrol Hypertens</i>. 2003;12(2):123-131. doi:10.1097/00041552-200303000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/12589171/pubmed" id="12589171" target="_blank">12589171</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17854366">
<a name="17854366"></a>Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). <i>Br J Dermatol</i>. 2007;157(5):989‐996. doi:10.1111/j.1365-2133.2007.08156.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/17854366/pubmed" id="17854366" target="_blank">17854366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32226335">
<a name="32226335"></a>Siegel JD, Ko CJ. Diltiazem-associated photodistributed hyperpigmentation. <i>Yale J Biol Med</i>. 2020;93(1):45-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/32226335/pubmed" id="32226335" target="_blank">32226335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15939821">
<a name="15939821"></a>Sitbon O, Humbert M, Jaïs X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. <i>Circulation</i>. 2005;111(23):3105-3111. doi: 10.1161/CIRCULATIONAHA.104.488486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/15939821/pubmed" id="15939821" target="_blank">15939821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34611920">
<a name="34611920"></a>Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. <i>Br J Clin Pharmacol</i>. Published online October 5, 2021. doi:10.1111/bcp.15060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/34611920/pubmed" id="34611920" target="_blank">34611920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8365158">
<a name="8365158"></a>Sousa-Basto A, Azenha A, Duarte ML, Pardal-Oliveira F. Generalized cutaneous reaction to diltiazem. <i>Contact Dermatitis</i>. 1993;29(1):44‐45. doi:10.1111/j.1600-0536.1993.tb04541.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/8365158/pubmed" id="8365158" target="_blank">8365158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12533163">
<a name="12533163"></a>Srivastava M, Rencic A, Diglio G, et al. Drug-induced, Ro/SSA-positive cutaneous lupus erythematosus. <i>Arch Dermatol</i>. 2003;139(1):45-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/12533163/pubmed" id="12533163" target="_blank">12533163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8135450">
<a name="8135450"></a>Steele RM, Schuna AA, and Schreiber RT. Calcium Antagonist-Induced Gingival Hyperplasia. <i>Ann Intern Med. </i>1994;120(8):663-664.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/8135450/pubmed" id="8135450" target="_blank">8135450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2523214">
<a name="2523214"></a>Stern R, Khalsa JH. Cutaneous adverse reactions associated with calcium channel blockers. <i>Arch Intern Med</i>. 1989;149(4):829‐832.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/2523214/pubmed" id="2523214" target="_blank">2523214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29521654">
<a name="29521654"></a>Subahi A, Ibrahim W, Abugroun A. Diltiazem-associated cardiogenic shock in thyrotoxic crisis. <i>Am J Ther</i>. 2018;25(6):e666‐e669. doi:10.1097/MJT.0000000000000739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/29521654/pubmed" id="29521654" target="_blank">29521654</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2031991">
<a name="2031991"></a>Tawashi M, Marc-Aurèle J, Bichet D, et al. Pharmacokinetics of intravenous diltiazem and five of its metabolites in patients with chronic renal failure and in healthy volunteers. <i>Biopharm Drug Dispos</i>. 1991b;12(2):105-112. doi:10.1002/bdd.2510120203<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/2031991/pubmed" id="2031991" target="_blank">2031991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2031997">
<a name="2031997"></a>Tawashi M, Marc-Aurèle J, Bichet D, et al. Pharmacokinetics of oral diltiazem and five of its metabolites in patients with chronic renal failure. <i>Biopharm Drug Dispos</i>. 1991a;12(2):95-104. doi:10.1002/bdd.2510120202<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/2031997/pubmed" id="2031997" target="_blank">2031997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2292178">
<a name="2292178"></a>Taylor JW, Cleary JD, Atkinson RC. Stevens-Johnson syndrome associated with diltiazem. <i>Clin Pharm</i>. 1990;9(12):948‐950.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/2292178/pubmed" id="2292178" target="_blank">2292178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Taztia.2014.06">
<a name="Taztia.2014.06"></a>Taztia (diltiazem) [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; June 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TaztiaXT.2017.10">
<a name="TaztiaXT.2017.10"></a>Taztia XT (diltiazem) [prescribing information]. Parsippany, NJ: Actavis Pharma, Inc; October 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tiazac.2016.11">
<a name="Tiazac.2016.11"></a>Tiazac (diltiazem) [prescribing information]. Bridgewater, NJ: Valeant; November 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tiazac.2017.10">
<a name="Tiazac.2017.10"></a>Tiazac (diltiazem) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; July 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-TiazacXC.2017.03">
<a name="TiazacXC.2017.03"></a>Tiazac XC (diltiazem) [product monograph]. Laval, Quebec, Canada: Bausch Health, Canada Inc; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25268343">
<a name="25268343"></a>Tuchinda P, Kulthanan K, Khankham S, Jongjarearnprasert K, Dhana N. Cutaneous adverse reactions to calcium channel blockers. <i>Asian Pac J Allergy Immunol</i>. 2014;32(3):246‐250. doi:10.12932/AP0380.32.3.2014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/25268343/pubmed" id="25268343" target="_blank">25268343</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9415262">
<a name="9415262"></a>Vicente-Calleja JM, Aguirre A, Landa N, Crespo V, González-Pérez R, Díaz-Pérez JL. Acute generalized exanthematous pustulosis due to diltiazem: confirmation by patch testing. <i>Br J Dermatol</i>. 1997;137(5):837‐839. doi:10.1111/j.1365-2133.1997.tb01139.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/9415262/pubmed" id="9415262" target="_blank">9415262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2564139">
<a name="2564139"></a>Waller PC, Inman WH. Diltiazem and heart block. <i>Lancet</i>. 1989;1(8638):617. doi:10.1016/s0140-6736(89)91644-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/2564139/pubmed" id="2564139" target="_blank">2564139</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3510525">
<a name="3510525"></a>Weiner DA, Cutler SS, Klein MD. Efficacy and safety of sustained-release diltiazem in stable angina pectoris. <i>Am J Cardiol</i>. 1986;57(1):6-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/3510525/pubmed" id="3510525" target="_blank">3510525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Hypertension</i>. 2018;71(6):e140-e144]. 2018;71(6):e13-e115. doi: 10.1161/HYP.0000000000000065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1445088">
<a name="1445088"></a>Wittal RA, Fischer GO, Georgouras KE, Baird PJ. Skin reactions to diltiazem [published correction appears in <i>Australas J Dermatol</i> 1992;33(2):86]. <i>Australas J Dermatol</i>. 1992;33(1):11‐18. doi:10.1111/j.1440-0960.1992.tb00047.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/1445088/pubmed" id="1445088" target="_blank">1445088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15234417">
<a name="15234417"></a>Zeltser D, Justo D, Halkin A, et al. Drug-induced atrioventricular block: prognosis after discontinuation of the culprit drug. <i>J Am Coll Cardiol</i>. 2004;44(1):105-108. doi:10.1016/j.jacc.2004.03.057<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/diltiazem-drug-information/abstract-text/15234417/pubmed" id="15234417" target="_blank">15234417</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zimetbaum.2019">
<a name="Zimetbaum.2019"></a>Zimetbaum PJ, Wylie JV. Nonsustained ventricular tachycardia: Clinical manifestations, evaluation, and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 4, 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9365 Version 808.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
